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ABSTRACT OF DISSERTATION 
 
 
 
 
THE DEVELOPMENT OF NOVEL NON-PEPTIDE  
PROTEASOME INHIBITORS FOR THE TREATMENT OF SOLID TUMORS 
 
 
The proteasome is a large protein complex which is responsible for the majority of 
protein degradation in eukaryotes. Following FDA approval of the first proteasome inhibitor 
bortezomib for the treatment of multiple myeloma (MM) in 2003, there has been an 
increasing awareness of the significant therapeutic potential of proteasome inhibitors in the 
treatment of cancer. As of 2017, three proteasome inhibitors are approved for the treatment 
of MM but in clinical trials with patients bearing solid tumors these existing proteasome 
inhibitors have demonstrated poor results. Notably, all three FDA-approved proteasome 
inhibitors rely on the combination a peptide backbone and reactive electrophilic warhead to 
target the proteasome, and all three primarily target the catalytic subunits conferring the 
proteasome’s chymotrypsin-like (CT-L) activity.  
It is our hypothesis that compounds with non-peptidic structures, non-covalent and 
reversible modes of action, and unique selectivity profiles against the proteasome’s distinct 
catalytic subunits could have superior pharmacodynamic and pharmacokinetic properties 
and may bear improved activity against solid tumors relative to existing proteasome 
inhibitors. In an effort to discover such compounds we have employed an approach which 
combines computational drug screening methods with conventional screening and classic 
medicinal chemistry. 
Our efforts began with a computational screen performed in the lab of Dr. Chang-Guo 
Zhan. This virtual screen narrowed a library of over 300,000 drug-like compounds down to 
under 300 virtual hits which were then screened for proteasome inhibitory activity in an in 
vitro assay. Despite screening a relatively small pool of compounds, we were able to identify 
18 active compounds. The majority of these hits were non-peptide in structure and lacked 
any hallmarks of covalent inhibition. The further development of one compound, a tri-
substituted pyrazole, provided us with a proteasome inhibitor which demonstrated cytotoxic 
activity in a variety of human solid cancer cell lines as well as significant anti-tumor activity 
in a prostate cancer mouse xenograft model. We have also evaluated the in vitro 
pharmacokinetic properties of our lead compound and investigated its ability to evade cross-
resistance phenomena in proteasome inhibitor-resistant cell lines. 
We believe that our lead compound as well as our drug discovery approach itself will 
be of interest and use to other researchers. We hope that this research effort may aid in the 
further development of reversible non-peptide proteasome inhibitors and may eventually 
deliver new therapeutic options for patients with difficult-to-treat solid tumors.  
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 INTRODUCTION 
1.1 Introduction and History of the Ubiquitin-Proteasome System (UPS) 
The discovery of the biological system now referred to as the ubiquitin-proteasome system 
can be traced back to the 1940’s when pioneering work by Schoenheimer showed that 
cellular proteins exist in a state of flux, being both continuously synthesized and continuously 
degraded. This corrected the prior view that cellular proteins were generally stable [1, 2]. In 
1955, the discovery of a new organelle known as the lysosome was reported by de Duve [3]. 
The lysosome is an acidic, membrane-bound organelle containing a variety of hydrolytic 
enzymes capable of degrading cellular proteins. This discovery, along with additional studies 
into the function of the lysosome, lead to the belief that the lysosome was chiefly responsible 
for cellular protein turnover [2]. It would not be until the late 1970’s that a more accurate 
picture of cellular protein degradation would begin to emerge with the discovery of the 
ubiquitin-proteasome system (UPS). 
When discussing the discovery of the ubiquitin-proteasome system, the work done by Aaron 
Ciechanover, Avram Hershko, and Irwin Rose in the 1970’s and 1980’s is of particular 
importance. Their efforts formed the basis for our modern understanding of the UPS and for 
this work they were awarded the 2004 Nobel Prize in Chemistry. Although we now 
understand that the UPS plays a key role in cellular protein degradation, including the 
regulation of many important signaling proteins, this knowledge was acquired gradually 
thanks to the publication of many seminal papers in 1970’s, 80’s, and 90’s. Much of this early 
work in unraveling the function of the ubiquitin-proteasome system was aided by the use of 
the rabbit reticulocyte system, a preparation from cells which lacked lysosomes yet which 
had the capability for ATP-dependent protein degradation [4]. In 1980, publications by 
Ciechanover et al. and Hershko et al. demonstrated that ATP-dependent protein degradation 
in the rabbit reticulocyte system relied on a small protein factor dubbed APF-1 which could 
be covalently linked to lysine ε-amino groups in target proteins via an isopeptide bond [5, 6]. 
This would result in the breakdown of those target proteins and the recycling of the APF-1 
protein. Later that same year, APF-1 was positively identified as the widely-distributed 8.5 
kDa protein ubiquitin [7]. By the mid-1980’s it was known that a cascade of three enzymes 
was responsible for the ATP-dependent conjugation of ubiquitin to a target protein and there 
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was strong evidence that ubiquitination was the key signal for non-lysosomal protein 
degradation [8, 9].  
At this point the protease or proteases responsible for the degradation of ubiquitin-tagged 
proteins were still unknown. Some of the first steps towards the discovery of the proteasome 
began with publications by Wilk et al. in 1979 and 1980 which reported the purification and 
characterization of an abundant neutral endopeptidase from bovine pituitaries. This 
endopeptidase was found to have an apparent molecular weight of 700 kDa and was believed 
to consist of multiple smaller subunits providing the protein complex with multiple distinct 
proteolytic activities [10, 11]. One of the major steps towards linking this protein complex 
with the ubiquitin tagging system came in 1986 when Hough et al. described the partial 
purification of a similar large proteolytic complex from rabbit reticulocyte lysate [12]. They 
demonstrated the ability of this complex to degrade ubiquitin-conjugated lysozyme in the 
presence of ATP, but not unconjugated lysozyme. This complex was dubbed the proteasome 
by Arrigo et al. in 1988 and in the following years numerous additional publications 
contributed to our modern understanding of the structure and function of the proteasome 
[13-16].  
We now know that ubiquitin is a key posttranslational modification used in numerous 
biological systems beyond just protein degradation, such as DNA repair and endocytic 
trafficking [17, 18]. Although a target protein can be tagged with a single ubiquitin molecule 
(monoubiquitination), the use of polymeric chains of ubiquitin is more frequently observed 
and these polyubiquitin chains can adopt different structures based on the particular choice 
of lysine residue used to link them together [19]. These distinct structural conformations 
allow for recognition by a variety of ubiquitin receptors which determine the biological fate 
of the ubiquitinated or polyubiquitinated protein [20, 21]. 
As mentioned previously, the process of attaching one or more ubiquitin polypeptides to a 
target protein involves a cascade of three enzyme types known as E1, E2, and E3 (Figure 1.1). 
E1 proteins, also known as ubiquitin-activating enzymes, first use ATP to activate ubiquitin 
(Ub) via C-terminal adenylation. Next the E1 enzyme’s catalytic cysteine (Cys) residue attacks 
the adenylated ubiquitin molecule, forming a E1~Ub complex via a thioester bond and 
releasing AMP. Once the E1 enzyme’s Cys residue is loaded with a ubiquitin molecule, it can 
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interact with an E2 enzyme and ubiquitin can be transferred to a catalytically-active Cys 
residue on the E2 protein via a transthiolation reaction yielding a covalent E2~Ub complex. 
The third step in the ubiquitination cascade involves the E3 enzyme, also known as a 
ubiquitin ligase. The human genome encodes over 600 putative E3 enzymes, and it is believed 
that this diversity of E3 enzymes allows the ubiquitin system to interact with a wide array of 
substrates and thus to regulate a large number of biological processes [22, 23]. Most 
eukaryotic E3 enzymes fall into one of two families, the RING (Really Interesting New Gene) 
finger domain family or the HECT (Homologous to the E6AP Carboxyl Terminus) domain 
family. The majority of known E3 enzymes utilize a RING finger domain in which the E3 
enzyme interacts with E2~Ub and mediates the direct transfer of ubiquitin from the E2 
enzyme to the lysine side chain of a target protein [24]. HECT domain E3 enzymes instead 
utilize a catalytic Cys residue and an additional transthiolation step to yield a covalent E3~Ub 
complex. Now charged with ubiquitin, the HECT domain E3 can transfer its ubiquitin 
molecule to a target protein. Once a target protein has been covalently tagged with a single 
ubiquitin molecule via an isopeptide bond (dubbed ‘initiation’), additional ubiquitin 
molecules can be attached to one of the lysine side chains present in the prior ubiquitin to 
build up a polyubiquitin chain via a step-wise process dubbed ‘chain extension’. In most but 
not all cases, polyubiquitin chains are built up sequentially on the target protein, rather than 
being preassembled and attached in a single reaction [25]. Once a target protein has been 
polyubiquitinated, it is poised for a recognition by a variety of ubiquitin-binding proteins 
which can carry out further modifications to the polyubiquitin chain or mediate downstream 
functions such as protein degradation [26].  
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Figure 1.1 Substrate ubiquitination via ubiquitin cascade 
Ubiquitination of a model substrate protein is mediated by E1, E2, and E3 enzymes. Repeated 
enzymatic cycles lead to the construction of a polyubiquitin chain on the target protein which 
serves as a signal for proteasomal degradation or other fates. 
 
Figure 1.2 Substrate ubiquitination via ubiquitin cascade 
Ubiquitination of a model substrate protein is mediated by E1, E2, and E3 enzymes. Repeated 
enzymatic cycles lead to the construction of a polyubiquitin chain on the target protein which 
serves as a signal for proteasomal degradation. 
 
Figure 1.3 Substrate ubiquitination via ubiquitin cascade 
Ubiquitination of a model substrate protein is mediated by E1, E2, and E3 enzymes. Repeated 
enzymatic cycles lead to the construction of a polyubiquitin chain on the target protein which 
serves as a signal for proteasomal degradation. 
 
Figure 1.4 Substrate ubiquitination via ubiquitin cascade 
Ubiquitination of a model substrate protein is mediated by E1, E2, and E3 enzymes. Repeated 
enzymatic cycles lead to the construction of a polyubiquitin chain on the target protein which 
serves as a signal for proteasomal degradation. 
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1.2 Structure and Function of the Proteasome 
 The 20S Proteasome 
The canonical form of the proteasome in eukaryotes is known as the 26S proteasome, based 
on its sedimentation rate. This 26S proteasome is large protein complex, approximately 
2.4 MDa, and can be dissociated into two main components, the 20S core proteasome particle 
and a 19S regulatory complex. The 20S core particle is responsible for the proteasome’s 
proteolytic activity and has a molecular weight of approximately 700 kDa. The 19S regulatory 
complex handles recognition of substrate proteins and the subsequent transfer of these 
substrates into the 20S proteasome, and will be discussed in greater depth below.   
Structurally, the 20S proteasome consists of a cylinder made from four stacked rings with 
each ring made from seven heteromeric subunits. X-ray crystallographic analysis has found 
that the mammalian 20S proteasome has an approximate overall length of 150 angstroms 
and an approximate diameter of 110 angstroms [27]. The cylinder is hollow internally, with 
the topmost and bottommost of the four stacked rings forming gates which segregate this 
space from the exterior environment. If we divide the cylinder horizontally between the two 
middle rings, we obtain two identical halves each consisting of 14 unique proteins forming 
two heptameric rings. In a complete 20S proteasome particle, the two outermost (top and 
bottom) rings are made from the α1-α7 subunits and are known as the alpha rings. The two 
inner rings are made from the β1-β7 subunits and are known as the beta rings (Figure 1.2). 
In total there are two copies each of 14 unique subunits, with subunits having individual 
molecular weights of approximately 20-30 kDa [28].  
Functionally, the 20S proteasome contains three types of proteolytically-active subunits, the 
β1, β2, and β5 subunits located in the two inner beta rings [29]. The active sites of these 
subunits face inward, accepting peptide substrates from the proteasome’s hollow inner 
chamber. By controlling which proteins enter its inner chamber, the proteasome is able to 
prevent non-specific degradation of cellular proteins [30]. These proteolytically-active 
subunits utilize an N-terminal threonine residue for their catalytic activity, placing them in 
the N-terminal nucleophile (Ntn) hydrolase family. These active threonine residues are 
initially masked by propeptide tails which serve both to prevent unregulated proteolytic 
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activity and which assist in assembly of the 20S proteasome complex [31]. The catalytically-
active β1, β2, and β5 subunits also possess distinct substrate specificities from one another. 
Traditionally these substrate preferences have been described as caspase-like (C-L) for β1, 
trypsin-like (T-L) for β2, and chymotrypsin-like (CT-L) for the β5 catalytic subunit. This is to 
say that the β1, β2, and β5 catalytic subunits generally prefer acidic, basic, and hydrophobic 
amino acids in the P1 position of their substrates, respectively [29, 32]. As a whole, a 20S 
proteasome particle contains six proteolytically active subunits (two copies each of the β1, 
β2, and β5 subunits) which degrade peptides which have entered its interior chamber.  Each 
catalytic subunit contains regions known as specificity pockets which interact with the amino 
acid side chains of peptide substrates. Peptide-based inhibitors of catalytic subunits also 
possess side chains which interact these specificity pockets. Differences in these specificity 
pockets provide the catalytic β-subunits with unique substrate preferences and also facilitate 
the design of subunit-selective proteasome inhibitors [33, 34]. Using the nomenclature 
described by Schechter and Berger, substrates have their residues or side chains labelled P1, 
P2, P3, etc. moving away from the scissile bond towards the peptide’s N-terminus. On the 
other side of the scissile peptide bond, residues or side chains are labelled P1’, P2’, P3’, etc. 
moving towards the peptide’s C-terminus [35]. Similarly the proteasome subunit’s specificity 
pockets which interact with these residues or side chains are labelled S1, S2, S3, etc. and S1’, 
S2’, S3’, etc. [36].  
Once a peptide substrate is bound to the active site of a β1, β2, or β5 subunit, the catalytic 
cycle can occur. Based on the quantum mechanical/molecular mechanical free energy 
calculations (QM/MM-FE) published by Wei et al. in 2013, the cycle is believed to begin with 
a water-assisted proton transfer from the catalytic N-terminal threonine’s oxygen (Thr1Oγ) 
to the N-terminal threonine’s free amino group (Thr1N) yielding a zwitterion. Now activated, 
the negatively charged Thr1Oγ attacks the carbonyl carbon of the substrate’s amide bond to 
generate a tetrahedral intermediate which, following a proton transfer, releases the C-
terminal portion of the substrate leaving behind an acyl-enzyme intermediate. Next this 
intermediate undergoes nucleophilic attack by water which eventually leads to the release of 
the N-terminal portion of the substrate as well as the regeneration of the catalytic Thr1 
residue [37]. The end result of this catalytic cycle is that proteins which are fed into the 
proteasome’s inner chamber are cleaved into smaller peptides. Kisselev et al. measured the 
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degradation products produced when 26S proteasomes purified from rabbit muscle were 
incubated with non-ubiquitinated casein and chemically-denatured IGF, ovalbumin, and 
lactalbumin. The resulting peptides ranged from approximately 3-22 residues with a log-
normal distribution and mean lengths of 6.5-9.0 residues. The high processivity of the 
proteasome is believed to result from the fact that the exit of small peptides from the 
proteasome’s inner chamber is diffusion-controlled [38].  
 
 The 19S Proteasome Regulatory Complex  
The work of recognizing polyubiquitinated substrate proteins, unfolding them, and then 
translocating them into the 20S proteasome’s inner chamber is handled by the 19S regulatory 
particle, also known as PA700 [39]. Evidence suggests that the 20S proteasome itself may be 
capable of degrading oxidized or damaged proteins, but the ability of cellular proteasomes to 
efficiently degrade ubiquitinated proteins requires the presence of the 19S regulatory 
particle [40]. The overall structure of the 19S regulatory particle consists of a lid subcomplex 
and a base subcomplex, and it is via this base subcomplex that the 19S particle interacts with 
the 20S proteasome’s alpha ring to form the larger 26S proteasome [41]. Due to the 20S 
proteasome’s two symmetrical halves, it is possible for 19S regulatory caps to simultaneously 
bind to both ends of the 20S proteasome forming a “19S-20S-19S” complex, also referred to 
as the 30S proteasome [42]. For simplicity, the term “26S proteasome” is frequently used to 
refer indiscriminately both to 19S-20S and 19S-20S-19S proteasome complexes.   
The 19S lid consists of at least nine non-ATP dependent subunits: Rpn3, Rpn5, Rpn6, Rpn7, 
Rpn8, Rpn9, Rpn11, and Rpn12. The 19S base consists of a ring of six homologous AAA-
ATPase subunits known as Rpt1-6 as well as the non-ATP dependent subunits Rpn1, Rpn2, 
Rpn10, and Rpn13 [28, 39] (Figure 1.2). The ATP-dependent Rpt subunits are believed to be 
involved in the unfolding of client proteins as well as the opening of the gate which otherwise 
blocks the free entry of substrates into the 20S proteasome’s inner chamber. The Non-ATPase 
Rpn-type proteins serve a variety of functions such as binding polyubiquitin (e.g. Rpn10 and 
Rpn13), interfacing with external ubiquitin-binding proteins (e.g. Rpn1), or cleaving 
ubiquitin off of client proteins in order to recycle ubiquitin for reuse [43-46]. Due to its 
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complexity and dynamic nature, some elements of the structure and the function of the 19S 
regulatory particle are not well understood and are generally beyond the scope of this work. 
  
 The Immunoproteasome and Thymoproteasome 
In addition to the β1, β2, and β5 catalytic subunits found in the 20S proteasome, four 
additional catalytic proteasome subunits are encoded in the human genome. These additional 
catalytic subunits are all believed to be involved in immune function and occur only in jawed 
vertebrates [47]. The first three additional subunits are the β1i, β2i, and β5i catalytic subunits 
which are the respective homologues of the β1, β2, and β5 subunits. The β1i, β2i, and β5i 
subunits have 59-71% amino acid sequence identity to their respective constitutive 
homologues [48]. When present in the cell, the β1i, β2i, and β5i catalytic subunits are capable 
of incorporating into newly-formed 20S proteasomes in place of the β1, β2, and β5 subunits 
giving rise to immunoproteasomes (Figure 1.4). The immunoproteasome is so named due to 
its presence in a wide variety of immune system cells and due to its ability to be induced upon 
exposure to certain inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and 
interferon gamma (IFN-γ) [49]. Amino acid substitutions in the specificity pockets alter the 
substrate specificity of the immunoproteasome and allow it to generate an alternative 
repertoire of peptide products. Although all of the mechanisms by which the 
immunoproteasome modulates immune function are not fully understood, it is known that 
the expression of immunoproteasome catalytic subunits leads to increased production of 
peptides with a hydrophobic C-terminal amino acid and decreased production of peptides 
with an acidic C-terminal amino acid [50, 51]. An increase in N-terminally extended peptides 
has also been reported [52]. These alterations in the proteasome’s cleavage pattern are 
consistent with the requirements for N-terminal trimming of potential antigens by ER 
aminopeptidase 1 (ERAP1) as well as the requirements for peptide binding to MHC Class I 
molecules [53-55]. Although there are known cases in which specific antigenic peptides are 
produced more readily by constitutive proteasomes, increased immunoproteasome 
expression generally leads to an increase in MHC Class I antigen presentation [56]. Additional 
evidence for the immunoproteasome’s role in antigen presentation and other facets of 
immune function come from observations of altered immune responses when one or more 
immuno-subunits are genetically knocked out [57-59]. Alterations in immunoproteasome 
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expression or activity have also been implicated in various pathophysiological conditions 
including cancer, inflammatory diseases, and neurodegenerative diseases making it an 
important area of research [60-63].  
The fourth and most recently discovered alternative catalytic subunit is β5t, a homologue of 
the β5 catalytic subunit with 50% amino acid sequence identity [48]. β5t is expressed 
specifically in cortical thymic epithelial cells (cTEC’s) where it is incorporated along with β1i 
and β2i to form thymoproteasomes. These thymoproteasomes have been shown to function 
in the positive selection of CD8+ T-cells via the generation of an altered repertoire of peptides 
which are displayed by MHC Class I proteins. The β5t subunit exhibits reduced chymotrypsin-
like activity and it has been hypothesized that this may aid in T-cell positive selection by 
generating weakly-bound or unstable peptide-MHC I complexes, however there is as yet little 
data available to verify this hypothesis [64, 65]. The precise mechanisms by which β5t 
expression aids CD8+ T-cell maturation are still an area of active research.  
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Figure 1.2 Structural diagram of the 26S proteasome 
The 26S proteasome consists of a 20S core particle and one or two 19S regulatory caps affixed 
at either end. The 20S core particle is constructed from four hepta-heteromeric rings, two 
α-rings and two β-rings. The 19S regulatory cap consists of a lid component and a base 
component. Polyubiquitinated substrates are recognized, unfolded, and degraded into short 
polypeptides by the 26S proteasome complex. Polyubiquitin tags are released as free 
ubiquitin monomers. 
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Figure 1.3 Proteasome catalytic site and Schechter and Berger nomenclature 
A hypothetical substrate peptide containing side chain substituents P1-P4 and P1’-P2’ 
interacting with the corresponding catalytic β-subunit specificity pockets denoted by blue 
semicircles, labeled S1-S4 and S1’-S2’. The scissile peptide bond is shown in red, with the 
catalytic β-subunit’s Thr1 residue positioned to attack the adjacent carbonyl carbon yielding 
a tetrahedral intermediate followed by peptide bond hydrolysis. 
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Figure 1.4 Cross-sectional view of constitutive and immunoproteasome β-rings 
A cross-sectional diagram of proteasome and immunoproteasome β-rings containing three 
catalytically-active β-subunits (β1, β2, and β5 or β1i, β2i, and β5i) as well as four catalytically-
inactive β-subunits. Exposure to IFN-γ or TNF-α triggers the synthesis of immunoproteasome 
catalytic subunits followed by their incorporation into newly synthesized proteasomes.  
 
 
 
 
Figure 1.47 Cross-sectional view of constitutive and immunoproteasome β-rings 
A cross-sectional diagram of proteasome and immunoproteasome β-rings containing three 
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1.3 Deubiquitination 
Before concluding our introduction to the ubiquitin-proteasome system, the reversible 
nature of ubiquitin tags must be discussed. As with most posttranslational modifications, 
ubiquitination is not an irreversible process and specific enzymes known as deubiquitinases 
(DUBs) exist to trim or remove mono- and polyubiquitin tags from proteins. Over 70 DUB’s 
are encoded in the human genome and they perform a number of key functions within the 
ubiquitin-proteasome system. These include the production of free ubiquitin from newly-
synthesized polymeric precursor proteins, the recycling of ubiquitin from proteins to be 
degraded, and the removal of ubiquitin tags from proteins preventing their degradation [66]. 
DUB’s also regulate non-proteasomal functions of ubiquitin tags such as DNA damage repair 
and endocytic trafficking of cell-surface receptors [67, 68]. DUB proteins are critical for the 
normal function of the ubiquitin-proteasome system and also act to regulate the half-lives of 
specific substrate proteins including key signaling proteins such p53, NF-κB pathway 
proteins, and Myc [69-71].  
 
1.4 The Discovery and Development of Proteasome Inhibitors 
The impetus to develop new and improved proteasome inhibitors has existed since the 
beginning of proteasome research. Initially proteasome inhibitors were used as tools to 
probe the proteasome’s function and its role in the cell, but by the late 1990’s there was 
evidence that proteasome inhibitors may have therapeutic potential for a number of 
indications. These included genetic diseases which involved protein degradation, immune 
and inflammatory diseases, skeletal muscle wasting, and cancer [72]. Known proteasome 
inhibitors will be discussed in this section, classified by warhead pharmacophore.  
 
 Peptide Aldehyde Inhibitors 
Many early studies on proteasome inhibition utilized peptides with a C-terminal aldehyde 
moiety which were already well known as inhibitors of serine (Ser) and cysteine (Cys) 
proteases [73-75]. Theory suggests that small molecules which act as analogues of a 
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protease’s transition state will bind more tightly than substrates, thus occupying the 
enzyme’s active site and consequently inhibiting the enzyme’s activity.  [76]. In the case of 
the proteasome catalytic subunits, the initial reaction between the catalytic threonine residue 
and a peptide substrate yields a tetrahedral acyl-enzyme intermediate. A subsequent 
hydrolysis step uses a water molecule to release the N-terminal portion of the substrate and 
regenerates the catalytic threonine nucleophile. When a peptide aldehyde reacts with the 
proteasome’s catalytic residue, a reversible covalent bond is formed yielding a tetrahedral 
hemiacetal. This hemiacetal is believed to mimic the transition state which occurs naturally 
in the hydrolysis step of the proteasome’s peptidase reaction. Peptide aldehyde inhibitors 
bind tightly and competitively inhibit proteasome catalytic subunits. The most common 
aldehyde proteasome inhibitors were designed based on di-, tri-, or tetrapeptides with a 
hydrophobic P1 residue. Aldehyde-based inhibitors of note include Z-LLF-CHO (Z = 
carboxybenzyl, CHO = aldehyde), LLnL (N-acetyl-LL-norleucine-aldehyde), and MG-132 (Z-
LLL-CHO) (Figure 1.5). These compounds all act as slow-binding reversible inhibitors of the 
proteasome’s chymotrypsin-like activity. The drawbacks of these compounds included their 
rapid metabolism of peptide aldehydes to inactive carboxylic acids in living cells, their 
generally low potency, and the rapid reversibility of their inhibition [77].  
 
 Peptide Boronic Acid Inhibitors 
Later work focused both on the development of alternative ‘warheads’ to replace the 
aldehyde moiety. A 1998 publication by Adams et al. was one of the first to report the 
usefulness of peptidyl boronic acids as proteasome inhibitors [78]. While boron is not 
commonly utilized in medicinal chemistry, peptide boronic acid analogues are known for 
their ability to inhibit a number of different serine proteases via the formation of coordinate 
or dative covalent bonds between the boron atom and the protease’s catalytic nucleophile 
[79]. Using a C-terminal boronic acid pharmacophore to target the proteasome’s catalytic 
threonine residue, Adams et al. described the optimization of a series of tripeptide boronic 
acids using natural and unnatural amino acids. Via this method they were able to generate 
highly potent inhibitors of the 20S proteasome’s chymotrypsin-like activity. They identified 
several inhibitors with Ki values in the 0.01 to 0.025 nM range, and Adams et al. demonstrated 
as much as 2,500-fold improvement in potency when replacing an aldehyde warhead with a 
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boronic acid warhead. Adams et al. also tested several other potential warheads such as 
ketobenzoxazole or di-keto ester warheads, however boronic acids were found to give the 
highest inhibitory potency and additionally offered superior selectivity for the proteasome 
over other protease families when compared to aldehyde inhibitors. As proven by X-ray 
crystallographic analysis of a peptide boronic acid bound to the 20S proteasome published 
by Groll et al. in 2006, a tetrahedral adduct is formed when the Thr1Oy nucleophile attacks 
the boron atom. Groll et al. also rationalized the greater selectivity of peptide boronic acid 
inhibitors for Thr and Ser proteases over Cys proteases via the Lewis hard-soft acid-base 
(HSAB) theory [80]. Due to sulfur’s lower density of charge as compared to oxygen, it is 
theorized to react slower and to form a weaker bond with boron-based warheads. Evidence 
also shows that boronic-acid proteasome inhibitors are capable of achieving high potency 
and relatively slow target dissociation rates. The FDA-approved boronic acid proteasome 
inhibitors, bortezomib and ixazomib (Figure 1.5), were found to have KI values of 0.55 and 
0.93 nM against the β5 catalytic subunit, respectively, as well as β5 dissociation half-lives of 
110 and 18 minutes, respectively [81]. Chronologically, bortezomib and ixazomib were the 
1st and 3rd proteasome inhibitors to receive FDA approval, and will be discussed in greater 
detail below. Other boronic acid-based proteasome inhibitors of note include the MG-262, the 
boronic acid analogue of MG-132, and delanzomib, an orally-available inhibitor whose 
development for the treatment of multiple myeloma was discontinued following poor phase 
I/II clinical trial results [82].  
 
 β-Lactone Inhibitors 
The next class of proteasome inhibitors to receive significant attention was the β-lactones. In 
1995 Fenteany et al. identified the proteasome β5 catalytic subunit as the primary binding 
target of the Streptomyces metabolite lactacystin (Figure 1.5). Additional experiments 
revealed that several proteasome catalytic subunits can be covalently and irreversibly 
labeled by an active β-lactone compound which is formed when lactacystin, itself inactive, 
undergoes intramolecular nucleophilic attack releasing N-acetylcysteine as a byproduct. This 
active compound, referred to as omuralide or clasto-lactacystin β-lactone, covalently 
modifies the Thr1 residue of multiple proteasome catalytic subunits causing potent and 
irreversible inhibition of the proteasome’s chymotrypsin-like activity as well as l inhibition 
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of its trypsin-like and caspase-like activities [83-85]. Analogues of omuralide were studied 
and one compound known as PS-519 was tested preclinically and in a phase I clinical trial for 
use as a neuroprotective agent in acute stroke [86]. Interest in β-lactone proteasome 
inhibitors was rekindled in 2003 with the discovery of the natural product proteasome 
inhibitor salinosporamide A produced by a marine actinomycete bacteria [87]. Sharing the 
same core structure as omuralide, salinosporamide A consists of a β-lactone ring fused to a 
γ-lactam ring (Figure 1.5). Salinosporamide A was found to inhibit the 20S proteasome 
approximately 35-fold more potently than omuralide and, unlike omuralide, had potent 
activity against all three proteasomal activities (CT-L, T-L, and C-L) [88]. Due to its inhibitory 
activity against the proteasome as well as potent cytotoxic activity against cancer cell lines, 
salinosporamide A was entered into clinical trials as an anticancer agent first under the name 
NPI-0052 and later as marizomib by Nereus Pharmaceuticals [89, 90]. Marizomib has been 
investigated in multiple phase I and phase I/II clinical trials beginning in 2006. Following the 
acquisition of marizomib by Celgene Corporation in late 2016, positive results from a more 
recent phase I trial of marizomib with pomalidomide and dexamethasone in relapsed and 
refractory MM were published in the British Jounral of Haematology [91]. A total of 38 
patients were treated with intravenous marizomib at doses of 0.3, 0.4, or 0.5 mg/m3. A 53% 
ORR was observed, with two patients (6%) achieving a very good partial response (VGPR). 
Treatment was well tolerated with neutropenia being the most common grade 3 or higher 
adverse event (29%). Another potential application of marizomib is in the treatment of 
malignant gliomas. In rats injected with 3H-marizomib, radioactivity levels in the CNS 
indicated that marizomib concentrations were approximately 30% of the steady-state blood 
concentration. Dosing healthy cynomolgus monkeys with oral marizomib produced 
significant reductions in pre-frontal cortex proteasome activity, further demonstrating 
marizomib’s ability to cross the blood-brain barrier [92]. A phase III trial of marizomib in 
combination with temozolomide and radiotherapy in glioblastoma patients is anticipated to 
begin in April 2018 [93].  
 
 Peptide Vinyl Sulfone Inhibitors 
Peptide vinyl sulfones are a class of compounds originally known for their covalent 
irreversible inhibition of cysteine proteases via the Michael reaction. In this case the catalytic 
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cysteine residue acts as a nucleophile and attacks the vinyl sulfone at its electrophilic 
β-carbon atom [94]. In 1997, Bogyo et al. reported the synthesis and evaluation of Z-L3VS, a 
tripeptide compound with a C-terminal vinyl sulfone warhead which reacts with the 
proteasome’s catalytic Thr1 residues thus inhibiting multiple catalytic activities of the 
proteasome [95] (Figure 1.6). This initial publication noted that peptide vinyl sulfones were 
more easily synthesized than β-lactone-based inhibitors and inhibited their targets 
irreversibly, unlike aldehyde and boronic acid-based compounds. These characteristics made 
it possible to tag vinyl sulfone inhibitors with labels such as biotin or radioiodine thus 
irreversibly labeling the proteasome catalytic subunits. Although peptide vinyl sulfones have 
not been pursued as candidates for therapeutic use, they have been used as activity-based 
probes of the proteasome in a number of academic studies. Notable examples include an in-
depth study of proteasomal substrate specificity using radiolabeled vinyl sulfones by Nazif et 
al. and a publication by Verdoes et al. which showed that a fluorophore-labeled vinyl sulfone 
inhibitor could penetrate living cells and tag active proteasomes for visualization [96, 97].  
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Figure 1.5 Chemical structures of aldehyde and β-lactone proteasome inhibitors 
Z-LLF-CHO and MG-132 are peptide aldehyde inhibitors. Bortezomib, ixazomib citrate, 
delanzomib, and MG-262 are peptide boronic acid inhibitors. Clasto-Lactacystin-β-lactone, 
PS-519, and salinosporamide A are β-lactone inhibitors. Lactacystin is an inactive precursor 
which forms the active β-lactone via the elimination of N-acetylcysteine and intramolecular 
attack.  
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 Peptide Epoxyketone Inhibitors 
Peptide epoxyketone proteasome inhibitors were first discovered as natural products. 
Eponemycin and epoxomicin were both discovered at Bristol-Myers Squibb in Tokyo based 
on their activity against B16 murine melanoma. Eponemycin, first reported in 1990, was 
produced by a Streptomyces strain whereas epoxomicin, reported in 1992, was produced by 
an uncharacterized actinomycete strain [98, 99]. Both compounds contain a C-terminal 
α’,β’-epoxyketone moiety and a peptide backbone capped with an N-acyl group (Figure 1.6). 
In order to uncover the biological targets of these compounds, a group working under Dr. 
Craig Crews at Yale University first synthesized an analogue of eponemycin in which the 
unsaturated dehydroleucine residue was replaced with a normal leucine residue [100]. After 
confirming that this compound, dihydroeponemycin, retained biological activity, a probe 
compound bearing an N-terminal biotin group was synthesized. Upon incubating this probe 
compound with lysed murine lymphoma cells, two biotin-tagged proteins were captured via 
an affinity column. Protein sequencing identified these proteins as the immunoproteasome 
catalytic subunits β1i and β5i [101]. Treating purified bovine 20S proteasomes with the 
unlabeled compound dihydroeponemycin confirmed its ability to inhibit all three 
proteasomal catalytic activities in a competitive and irreversible fashion. A similar effort 
using biotinylated epoxomicin also identified proteasome and immunoproteasome catalytic 
subunits as the sole binding partners of epoxomicin. In this case β2, β5, β2i, and β5i were 
identified as bound by the epoxomicin-based probe compound [102]. Soon after, X-ray 
crystallographic analysis of epoxomicin bound to the proteasome revealed the formation of 
a 6-membered morpholino ring between the inhibitor and the active Thr1 residue [103]. 
More recently, high-resolution X-ray structures of human 20S proteasomes treated with 
three different peptide epoxyketone inhibitors instead revealed a 7-membered 1,4-
oxazepane ring between the each inhibitor and the catalytic Thr1 residue, thus leading to a 
revised mechanism for action for epoxyketone proteasome inhibitors [104]. As described in 
a 2016 review article by Carmony et al., proteasome inhibition by peptide epoxyketones is 
believed to be a two-step process which begins with an attack of Thr1Oγ on the epoxyketone 
carbonyl carbon followed by an attack of Thr1N on the epoxide ring’s β-methylene carbon 
leading to epoxide ring opening and formation of the 7-membered ring [105]. This final 
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adduct is stable thus providing irreversible inhibition of the catalytic site. Peptide 
epoxyketone inhibitors have been utilized as tool compounds in a number of studies. 
Examples include the use of fluorescent BODIPY-tagged epoxyketone proteasome inhibitors 
as imaging probes for specific catalytic subunits and the use of fluorophore-tagged 
epoxyketones as FRET pairs to examine the makeup of proteasomes which include mixtures 
of immuno- and constitutive catalytic subunits [106, 107]. A peptide epoxyketone of 
significant note is carfilzomib, a synthetic analogue of epoxomicin with potent anti-myeloma 
activity which was the 2nd proteasome inhibitor to receive FDA approval [108] (Figure 1.6). 
 
 
 
 
 
 
 
Figure 1.6 Chemical structures of vinyl sulfone and epoxyketone proteasome inhibitors 
Z-L3-VS is a peptide vinyl sulfone inhibitor. Eponemycin, epoxomicin, and carfilzomib are 
peptide epoxyketone inhibitors. 
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1.5 The Development of Subunit-Selective Proteasome Inhibitors 
Due to the multi-subunit nature of the proteasome, genetic knockouts of individual catalytic 
subunits may have undesired consequences such as increased incorporation of the 
homologous immunoproteasome catalytic subunit in their place or an overall decrease in the 
assembly of 20S proteasomes. Because chemical inhibition of specific proteasome catalytic 
subunits does not appear to affect the overall structure of the 20S proteasome or its assembly, 
it has been a preferred method for studying the function of individual catalytic subunits. 
There is also the potential that specific proteasome catalytic subunits may play pathological 
roles in diseases which could be inhibited by small molecules. Thus there has been an ongoing 
drive to develop subunit-selective proteasome inhibitors.  
 
 Chymotrypsin-like (β5/β5i) Selective Inhibitors 
Both the constitutive β5 and the β5i immunoproteasome catalytic subunits contribute to the 
proteasome’s chymotrypsin-like (CT-L) activity, albeit with some alterations in substrate 
preference between them such as a greater tolerance for a P1 Ala substituent for β5 and a 
greater tolerance for a P3 Pro substituent for β5i. Inhibitors which non-selectively target the 
β5 and β5i catalytic subunits are some of the oldest and best-studied proteasome inhibitors, 
going back to early peptide aldehyde inhibitors such as MG-132 which target both β5 and β5i 
in large part due to the presence of a hydrophobic leucine residue at the inhibitor’s P1 
position. The FDA-approved peptide epoxyketone carfilzomib is a potent inhibitor of β5 and 
β5i with IC50’s of 0.89 and 1.3 nM, respectively, and demonstrates >13-fold selectivity over 
other catalytic subunits when measured in cell lysate [32].  
 
 Trypsin-like (β2/β2i) Selective Inhibitors 
Unlike the β1i and β5i immuno-subunits, β2i is reported to have no differences in its 
substrate binding pockets relative to its counterpart β2 except for the substitution of 
Asp53Glu, a residue which contributes to the character of the S1 pocket [34]. Due to the 
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presence of a negatively-charged residue in the S1 pocket, both subunits prefer to cleave 
substrates with positively-charged residues in the P1 position. Due to their similar binding 
pockets the β2 and β2i catalytic subunits are likely to have highly similar substrate 
specificities and thus the task of creating fluorogenic substrates or inhibitors which 
selectively target β2 or β2i is very difficult. Although inhibitors containing a P1 Arg residue 
have long been known to preferentially inhibit proteasomal trypsin-like activity, peptides 
containing highly-charged amino acids such as Arg are also more likely to suffer from poor 
cell permeability [109]. Data from Mirabella et al. provide examples of known T-L-selective 
inhibitors and may also exemplify this effect on permeability. Two tripeptide epoxyketones 
known as NC-012 and NC-022 were tested against purified 26S proteasomes as well as intact 
H929 cells. NC-012 and NC-022 are tripeptide epoxyketones with the peptide sequence 
N-acetyl-Arg-Leu-Arg and hydroxymethylbenzoyl-Val-Ser-Arg. While NC-012 was more 
potent than NC-022 in purified proteasomes (~0.1 µM vs. ~0.3 µM), NC-012 showed 
significantly lower potency against whole cells (~8 µM vs. ~0.02 µM) [110]. Both compounds 
demonstrated >100x selectivity for trypsin-like (T-L) activity versus chymotrpysin-like 
(CT-L) and caspase-like (C-L) activity, and NC-022 showed minimal off-target activity in 
whole cells at doses up to 30 µM. Nonetheless these compounds still suffered from reportedly 
poor stability due to cyclization reactions with the Arg side chain, variable cell permeability, 
and difficult synthesis. A more recent paper from Mirrabella et al.’s group sought to overcome 
these issues by switching to a non-guanidino P1 substituent and a vinyl sulfone warhead 
[111]. Their lead compound known as LU-102 utilized L-leucine residues at the P2 and P3 
positions combined with a non-natural 4-aminomethylphenyalanine residue in the P1 
position to achieve an IC50 of 3.8 nM against purified proteasomes and potent and selective 
inhibition of T-L activity in whole cells. More recently there has been a report of a pair of 
inhibitors selective for β2 over β2i and vice versa with reported selectivity ratios of greater 
than 10:1 for both compounds [112]. Interestingly these two compounds have significant 
structural differences utilizing different C-terminal warheads, different substituents at the 
P1, P2, and P3 positions, and different N-terminal caps. To date the selectivity of these two 
compounds has only reported via an activity-based profiling method in Raji cell lysates so 
further evaluation of their selectivities via multiple methods is warranted.  
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 Caspase-like (β1) Selective Inhibitors 
When comparing the β1i catalytic subunit to the β1 subunit, there are significant differences 
in the S1 specificity pocket of β1i, including the Arg45Leu substitution, which reduce the 
pocket’s affinity for acidic amino acid side chains and decrease its size [34]. These alterations 
result in the β1i subunit having greatly reduced C-L activity as compared to β1 and a 
concomitant increased its chymotrpysin-like activity. This also aligns with the report by 
Blackburn et al. that the synthetic peptide substrates Z-Leu-Leu-Glu-AMC and Ac-Pro-Ala-
Leu-AMC (AMC = aminomethylcoumarin) act as specific substrates of β1 and β1i, respectively 
[113]. A publication by Kisselev et al. in 2003 examined the relative preference of the β1 
catalytic subunits for substrates containing Asp or Glu in the P1 position and found that the 
Asp-containing peptide Ac-GPLD-AMC was hydrolyzed approximately two-fold faster than 
the corresponding Glu-containing substrate. Via the use of a positional scanning library of 
proteasome substrates, Ac-nLPnLD-AMC (nL = norleucine) was identified as a good substrate 
of β1 and the corresponding C-terminal aldehyde was identified as a potent inhibitor of β1 
with a Ki of 0.40 µM [114]. Unfortunately, due to the generally rapid metabolism of aldehydes 
in living cells, the usefulness of this compound in vivo is likely to be limited. In 2016, data on 
a peptide epoxyketone inhibitor of β1 known as LU-001c were published [112]. Structurally, 
LU-001c is azidoacetyl-APnLD-ek (ek = epoxyketone) and had an IC50 of 65.5 nM against β1 
in Raji cell lysates and an IC50 of >1000 nM against all other catalytic subunits. Unfortunately, 
no inhibition was detected when live cells were treated with LU-001c suggesting a lack of cell 
permeability. Due to the apparent requirement of an acidic P1 residue for high potency and 
specificity towards β1 and the apparent negative effect of acidic residues on peptide cell 
permeability, a novel strategy may be necessary to create a β1 inhibitor which is suitable for 
in vivo use.  
 
 β1i-Selective Immunoproteasome Inhibitors 
Following the observation that the peptide epoxyketone natural product eponemycin and its 
dihydro analogue demonstrated a preference for β1i over other subunits, our laboratory 
examined the structure-activity relationship (SAR) for β1i inhibition using eponemycin 
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analogues [115]. A series of N-acyl dipeptide epoxyketones were synthesized which were 
closely related to eponemycin but which included a variety of substituents at the P1’ hydroxyl 
group. The lead compound, dubbed UK-101, utilized a P1 Leu residue, a P2 Ala residue, and a 
tert-butyldimethylsilyl (TBDMS) group at the P1’-OH position. This compound completely 
inhibited the binding of an activity-based probe to the β1i subunit at 1 µM but did not 
significantly inhibit other catalytic subunits at concentrations of up to 10 µM. More recent 
data on UK-101’s IC50’s against constitutive and immunoproteasome catalytic subunits was 
obtained using a set of fluorescently-tagged activity-based probes selective for the β1, β1i, 
β5, and β5i subunits. These experiments showed that UK-101 was highly selective for β1i as 
compared to β1, with an IC50 ratio of 144:1, but had only moderate selectivity for β1i over β5 
with a 10:1 selectivity ratio [116]. Our group has also investigated the previously-reported 
caspase-like inhibitor YU-102 (Ac-GPFL-epoxyketone) and found it to have β1i:β1 and β1i:β5 
selectivity ratios of 4.2:1 and >100:1 when measured using subunit-selective fluorogenic 
peptide substrates (unpublished data) [117]. Via modification of the P2, P4, and N-terminal 
substituents we were able to generate compounds with improved potency (β1i IC50 = 28 nM) 
and greater β1i:β1 selectivity (20.8:1).  
A report of efforts to optimize peptide epoxyketones for β1i selectivity was published by de 
Bruin et al. in 2014 [116]. Based on an initial scaffold similar to YU-102, utilizing P3 Pro and 
P1 Leu residues, they identified a tetrapeptide compound LU-001i as a highly specific 
inhibitor of β1i. In particular, the modifications of the P3 Pro residue to 4,4-difluoroproline 
and of the P1 Leu residue to cyclohexylglycine resulted in significant improvements to 
selectivity, albeit with a minor loss in potency. LU-001i was reported to have a 252-fold 
selectivity for β1i over β1 and a >200-fold selectivity for β1i over β5 and β5i. LU-001i is likely 
to be a useful probe of β1i function and has already been used to investigate the effects of 
several FDA-approved proteasome inhibitors on β1i activity in primary cells from acute 
lymphocytic leukemia patients [112].  
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Figure 1.7 Chemical structures of inhibitors targeting β2/β2i (T-L activity), β1, and β1i 
NC-012, NC-022, and LU-012 selectively inhibit the proteasome’s trypsin-like (T-L) activity 
which is conferred by the β2 and β2i catalytic subunits. Ac-nLPnLD-CHO and LU-001c 
selectively inhibit the constitutive proteasome β1 subunit. UK-101, YU-102, and LU-001i 
selectively inhibit the immunoproteasome β1i subunit with varying degrees of selectivity. 
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 β5i-Selective Immunoproteasome Inhibitors 
A medicinal chemistry effort undertaken by Proteolix Inc. resulted in a β5i-selective peptide 
epoxyketone inhibitor known as IPSI (immunoproteasome-selective inhibitor) or later as PR-
924 (Proteolix compound #924) (Figure 1.8). As described in their 2009 publication, the 
potency and selectivity of IPSI was determined via an assay known as ProCISE in which a 
combination of a non-selective irreversible biotin-tagged inhibitor and subunit-specific 
antibodies allows for the measurement of all six proteasome catalytic subunit activities in cell 
lysates [118]. IPSI had an IC50 of 22 nM against β5i and 132-fold selectivity over β5. Selectivity 
against other catalytic subunits was greater than 300-fold in all cases. This initial report on 
IPSI also showed that a β5i-selective concentration (270 nM) of IPSI did not significantly 
reduce the cell viability or induce caspase-3/7 activity in several hematologically-derived 
cancer cell lines. Although a later publication did demonstrate that IPSI/PR-924 was 
cytotoxic in established cell lines and primary samples of multiple myeloma, the inhibitor 
concentrations required to observe these effects were in the non-selective range (≥1 µM). 
PR-957 is a second Proteolix-developed β5i-selective inhibitor (Figure 1.8). Although PR-957, 
later known as ONX 0914, is less potent and less selective than PR-924, in our laboratory’s 
observations it has substantially better aqueous solubility, as might be expected based on 
structural differences between the two compounds [119]. A 2009 Nature Medicine 
publication showed that i.v. administration of PR-957 in mice inhibited blood and tissue β5i 
activity, altered immune response, and significantly reduced severity of disease symptoms in 
a mouse model of rheumatoid arthritis while producing minimal toxicity [119]. 
Investigations into the potential therapeutic applications of β5i inhibitors in autoimmune 
disease are ongoing [63].  
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Figure 1.8 Chemical structures of inhibitors targeting the β5 and β5i subunits 
PR-924 (IPSI) and PR-957 (ONX 0914) are β5i-selective epoxyketones. CPSI, LU-005c, and 
LU-015c are β5-selective peptide epoxyketones.  
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 β5-Selective Proteasome Inhibitors 
CPSI (Constitutive proteasome selective inhibitor) is a β5-selective inhibitor discovered by 
Proteolix Inc. as a part of their efforts to design an orally-bioavailable analogue of carfilzomib 
(Figure 1.8) [120]. Assayed using ProCISE, CPSI had a β5 IC50 of 17 nM and moderate 
selectivity over β2i and β5i (13- and 21-fold, respectively). As was the case for IPSI, CPSI alone 
at a selective dose (180 nM) did not cause cell death or induce caspase-3/7 activity, whereas 
non-selective inhibitors such as carfilzomib or a combination of IPSI plus CPSI did [118]. 
These data support the overarching hypothesis that the inhibition of an individual 
proteasome catalytic subunit is not sufficient to effectively induce cell death. LU-005c and 
LU-015c are a pair of related peptide epoxyketone inhibitors which specifically inhibit β5 
(Figure 1.8). Using Raji cell lysates, LU-005c was determined to have a β5 IC50 of 22.9 nM with 
IC50’s of >1000 nM against all other catalytic subunits. Due to a lack of any observed inhibition 
in intact cells, LU-015c was developed by replacing LU-005c’s N-terminal cap with the 
hydrophilic 2-morpholino acetic acid cap found in the FDA-approved proteasome inhibitor 
carfilzomib and by extending the inhibitor’s length via the insertion of an L-leucine residue 
in the P4 position. Although these modifications reduced potency by 6.5-fold and resulted in 
a somewhat less favorable β5:β5i selectivity ratio of 52:1, it did result in a compound which 
was suitable for use in intact cells such as live primary leukemia cells [112].   
 
1.6 The Clinical Development of Proteasome Inhibitors 
Although we now know that the ubiquitin-proteasome system is involved in a multitude of 
diseases, a key motivation for the early development of proteasome inhibitors was their 
potential ability to treat muscle wasting. The path to the first FDA-approved proteasome 
inhibitor began with research into the role of the ubiquitin-proteasome system in muscle 
wasting conducted in the lab of Alfred L. Goldberg at the Harvard Medical School. A review 
article by Mitch and Goldberg published in the New England Journal of Medicine in 1996 
summarizes several studies which identified increased activity of the UPS in animal models 
of various catabolic states [121]. They also identified a number of important human 
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conditions which may involve pathological muscle wasting such as AIDS, Cushing’s 
syndrome, neuromuscular disease, and cancer. Mitch and Goldberg hypothesized that partial 
pharmacological inhibition of the proteasome could limit excessive proteolysis in these 
conditions without excessively impairing cellular function. Based on this hypothesis, 
research to develop proteasome inhibitors suitable for clinical use began.  
 
 Bortezomib 
In an effort to develop and commercialize proteasome inhibitors as therapies in muscle 
wasting diseases, Goldberg founded Myogenics in 1993. It was at Myogenics where some of 
the notable peptide aldehyde inhibitors of the proteasome such as MG-115 and MG-132 were 
discovered and it was these compounds that would eventually serve as the basis for the first 
FDA-approved proteasome inhibitor bortezomib [122]. Julian Adams was hired as head 
chemist in 1994, and research into boronic acid-based proteasome inhibitors was conducted 
under his lead. This quickly led to the discovery of the dipeptidyl boronic acid known 
originally as MG-341 which would eventually become the first FDA-approved proteasome 
inhibitor, not for the treatment of muscle wasting diseases, but rather for an entirely different 
application.  
A 1994 Cell publication by Goldberg and Tom Maniatis of Harvard University showed that 
proteasome plays an essential role in the activation of the NF-κB transcription factor via both 
the degradation of the inhibitory factor IκBα and the processing of the inactive p105 
precursor protein to the active protein product p50 [123]. In live HeLa cells, peptide aldehyde 
proteasome inhibitors were able to cause a large reduction in NF-κB activation following 
stimulation. Due to NF-κB’s critical role in immune response and inflammation, it was a drug 
target of significant interest [124]. Based in part upon these observations, Myogenics shifted 
its focus from muscle wasting to inflammation and changed their name to ProScript to reflect 
this new focus. Alongside this rebranding, the proteasome inhibitor previously known as 
MG-341 was renamed to PS-341. It was also in 1994 that Avram Hershko, Nobel Prize winner 
for this research into the UPS, suggested to Goldberg that ProScript should investigate the 
potential applications of proteasome inhibitors as anticancer therapies. Although there was 
little published information linking proteasome function to cancer at that time, ProScript 
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began investigating cancer as a potential therapeutic area for proteasome inhibitors, while 
reportedly maintaining interest in inflammation and NF-κB as well.  
Two significant studies which were among the first to support the effectiveness of 
proteasome inhibitors were published in 1999. These two publications resulted from 
collaborations between ProScript researchers and scientists at the National Cancer Institute 
(NCI) and the Dana-Farber Cancer Institute, respectively. The first of these papers detailed 
the results of 13 boronic acid proteasome inhibitors which had been screened against the 
NCI’s panel of 60 cancer cell lines known as the NCI-60 [125]. Although these compounds 
spanned a wide range of proteasome inhibitory activity (Ki = 0.1-2300 nM), there was high 
degree of correlation between each compound’s activity against purified 20S proteasomes 
and its average growth inhibitory activity against the NCI-60 panel. Of these compounds, PS-
341 was the most potent against the cell line panel with an average growth inhibitory 
concentration (GI50) of 6.3 nM. Following these results, PS-341 was tested against mice 
bearing tumor xenografts. This study showed that a single i.v. injection of 0.3 mg/kg PS-341 
could significantly inhibit proteasome activity in white blood cells and in PC-3 tumor cells. 
Four direct injections of 1 mg/kg PS-341 into PC-3 tumors on a daily or weekly schedule 
significantly reduced tumor volume as compared to vehicle. A publication by Teicher et al. 
published three months later demonstrated similar results: PS-341 was cytotoxic to cancer 
cells both in vitro and in mouse models with relatively high potency [126].  
Following the promising preclinical results of PS-341, human clinical trials were begun. A 
number of phase I clinical trials of PS-341 were conducted, using patients with solid tumors 
as well as patients with hematological cancers. According to Adams et al. in a 2002 review, 
data from approximately 200 patients treated in phase I trials indicated that PS-341 was well 
tolerated but with reports of low-grade fever, fatigue, thrombocytopenia, and in some cases, 
peripheral neuropathy [127]. Adams et al. also noted anecdotal reports of efficacy in non-
small cell lung cancer, melanoma, and multiple myeloma. 
PS-341 changed ownership twice during its clinical development, first from ProScript to 
LeukoSite in 1999. Several months later LeukoSite was purchased by Millenium 
Pharmaceuticals for reasons unrelated to PS-341, and PS-341’s development was deemed a 
low priority [122]. According to previously-cited review by Sanchez-Serrano, it was a single 
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promising result in a multiple myeloma patient, a 47-year old woman with advanced disease 
who achieved complete remission as a part of the phase I trial conducted at the University of 
North Carolina [122, 128]. During its clinical development at Millenium, PS-341 received the 
nonproprietary name bortezomib and was eventually marketed under the brand name 
Velcade®.  
Phase II clinical trials of PS-341 examined its efficacy in several different cancer types, but in 
hindsight it is multiple myeloma which is of the most interest due to the eventual FDA 
approval of PS-341 to treat relapsed and refractory multiple myeloma. SUMMIT was a phase 
II open-label non-randomized trial of bortezomib which enrolled 202 patients with relapsed 
multiple myeloma which was refractory to the last agent used in 91% of patients. Patient 
enrollment was performed between February and December 2001. Bortezomib was dosed 
intravenously at 1.3 mg per square meter of body-surface area (mg/m3) twice weekly for two 
weeks per 21-day cycle. Bortezomib was used as a single agent except in patients with 
progressive or stable disease after four cycles who were eligible to receive supplemental 
dexamethasone (Dex). Among the evaluable patients, the overall response rate (ORR) was 
35% with 4% (n=7) of patients achieving complete response (CR) and 6% (n=12) of patients 
achieving a near-complete response (nCR). The median duration of response (DOR) for 
patients achieving any response was 12.7 months. Median overall survival for the entire 
population was 17.0 months [129]. Compared to historical response and survival data in 
similar patient populations, bortezomib’s activity was promising. 
In May 2003, FDA fast-track approval for the use of bortezomib in relapsed and refractory 
multiple myeloma patients was granted based primarily on data from the phase II SUMMIT 
trial. Further evidence of bortezomib’s activity in relapsed multiple myeloma (MM) was 
provided by the 669-patient randomized APEX trial which compared bortezomib versus 
high-dose Dex. Combined complete and partial response (CR and PR) rates were 38% and 
18% for bortezomib and Dex, respectively. Median times to progression were 6.22 and 3.49 
months, respectively. After one year of follow-up, there was a significantly greater rate of 
overall survival (p=0.003) in patients treated with bortezomib (80% rate) as compared to 
high-dose Dex (66% rate). Although bortezomib treatment was associated with a number of 
adverse events, publication such as the 2005 review by Bladé et al. already deemed it a “safe 
and highly effective drug to be added to the current treatment strategies for multiple 
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myeloma” [130]. By 2004 bortezomib was already seeing significant clinical use in with 
annual sales of $143 million in the US and bortezomib continues to see significant clinical use 
today. 
 Carfilzomib 
The second proteasome inhibitor to receive FDA approval was carfilzomib. The development 
of carfilzomib can be traced back to the discovery of the natural product epoxomicin in 1992 
by Bristol-Myers Squibb Japan. Due to its potent in vivo activity against murine melanoma, 
the lab of Craig Crews at Yale University began evaluating epoxomicin as a modulator of 
tumor growth signaling pathways. Based on the hypothesis that epoxomicin’s epoxyketone 
group was responsible for covalently modifying target proteins, the Crews lab synthesized a 
biotin-labeled analogue of epoxomicin and used it to pull down potential target proteins. This 
experiment revealed that the proteasome’s catalytic subunits were covalently modified by 
epoxomicin, and further work found that epoxomicin had exceptional selectivity for the 
proteasome over other common proteases. This excellent selectivity is now believed to be the 
result of a unique two-step inhibition mechanism in which epoxomicin or similar peptide 
epoxyketones are able to covalently modify both the catalytic Thr1O atom as well as the N-
terminal amino group forming a six-membered morpholino ring. Such a reaction would not 
be possible with a non-N-terminal nucleophile protease.  
Further work in the Crews lab focused on the optimization of epoxomicin’s anticancer activity 
via traditional medicinal chemistry [131]. By modifying the P2, P3, and P4 amino acid side 
chains they arrived at a tetrapeptide epoxyketone dubbed YU-101. According to a 2013 
retrospective by Crews and his former mentee Kim, YU-101 had better potency against the 
proteasome and more potent antitumor activities than bortezomib [132]. Based upon 
YU-101’s superior potency and reports of bortezomib’s ongoing successes in clinical trials, 
Proteolix Inc. was established to develop YU-101 as an anticancer therapeutic. Work at 
Proteolix identified that, as with many other highly-hydrophobic peptides, YU-101 has poor 
water solubility (< 1 µg/mL) that could reduce its usefulness as a therapeutic agent. Further 
medicinal chemistry efforts were undertaken at Proteolix to optimize YU-101’s solubility, 
yielding the lead compound PR-171 via swapping YU-101’s N-terminal acetyl cap for the 
more polar and ionizable 2-morpholinoacetic acid group [133].  
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In a 2007 publication by Demo et al. of Proteolix, PR-171 was reported to have greater than 
1000-fold improved water solubility relative to YU-101 while retaining potent inhibitory 
activity against proteasome chymotrypsin-like activity (IC50 = 6 nM). PR-171 also 
demonstrated potent cytotoxic activity in a variety of cell lines with hallmark signs of 
proteasome inhibition such as polyubiquitin accumulation and upregulation of p21. Moving 
onto studies in mice, Demo et al. established that PR-171 could be administered to mice on 
two consecutive days (QDx2) to achieve a cumulative inhibition of proteasomal activity 
without excessive toxicity. This is in contrast to the typical clinical and preclinical use of 
bortezomib in which the drug is dosed on days 1 and 4 of each week, allowing for recovery of 
proteasome activity between doses. When comparing consecutively-dosed PR-171 to non-
consecutively dosed bortezomib in three groups of mice bearing different types of human 
tumor xenografts, 5 mg/kg PR-171 was found to have a significantly greater effect on tumor 
volume than 1 mg/kg bortezomib well remaining well-tolerated [133].  
Based on positive preclinical results, Proteolix moved forward with phase I clinical trials of 
PR-171 under the generic name carfilzomib. Starting in the fall of 2005, two phase I dose-
escalation trials of single-agent carfilzomib were conducted in patients with relapsed or 
refractory hematologic malignancies with a QDx5 and a QDx2 dosing cycle, respectively. The 
results of these studies established a three-week QDx2 dosing cycle with one week of rest 
(days 1, 2, 8, 9, 15, and 16 per 28-day cycle) as the preferred schedule and established the 
safety of carfilzomib i.v. infusions at doses up to 27 mg/m3. During the course of the QDx2 
phase I PX-171-002 trial, strong anti-myeloma activity was identified in five MM patients 
treated with 27 mg/m3 carfilzomib. Adverse reactions were also noted at this dose including 
cyclic thrombocytopenia and transient increases in creatinine consistent with an infusion-
like reaction [134]. 
Going forward, an open-label phase II pilot study of carfilzomib in patients with relapsed and 
refractory multiple myeloma was conducted (PX-171-003) with 46 enrolled patients as 
reported by Jagannath et al. in 2012 [135]. Based on early results from the PX-171-002 dose-
escalation study, a dose of 20 mg/m3 was chosen. Patients received 20 mg/m3 carfilzomib 
twice per week on consecutive days as a 2-minute i.v. infusion. Low-dose dexamethasone was 
administered prior to carfilzomib during the first cycle and as needed thereafter. Based on 
data from 42 evaluable patients, single-agent carfilzomib had activity deemed encouraging. 
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Specifically, 7 patients achieved PR (16.7%), 3 patients achieved MR (7.1%), and 17 patients 
had stable disease (SD, 40.5%). The ORR was 16.7% and the median duration of response 
was 7.2 months for the ORR population, favorable results in the context of this heavily pre-
treated population with a 100% rate of exposure to bortezomib and a 91% rate of exposure 
to lenalidomide (Len). Later results from PX-171-002 identified that the true maximum 
tolerated dosage was greater than expected, 27 mg/m3. Based on this new knowledge, PX-
171-003 was expanded with an additional 266 patients who were dosed at 20 mg/m3 for the 
first cycle followed by 27 mg/m3 in additional cycles. The reduced dose in cycle 1 was 
intended to mitigate previously-reported first-dose infusion reactions. According to the ASH 
abstract published Siegel at al. in 2010, the ORR was 24% and the median DOR was 7.4 
months [136]. As with the pilot study, this patient population was heavily pretreated with a 
median of 5 lines of prior therapy.  
An additional phase II study (PX-171-004) was conducted with a population consisting 
mainly of bortezomib-naïve patients. The results for bortezomib-naïve and bortezomib-
treated patients were published separately, however I will only discuss the former here. A 
total of 129 bortezomib-naïve patients were treated using single-agent carfilzomib in two 
separate cohorts. 94 patients in cohort 1 received carfilzomib at a steady dose of 20 mg/m3. 
A second cohort of 70 patients received carfilzomib at the 20/27 mg/m3 stepped dose 
mentioned above. The ORR was 42% and 52% in cohorts 1 and 2, respectively. The median 
time-to-progression (TTP) and median DOR was 13.1 months and 8.3 months in cohort 1. 
Neither median TTP nor median DOR were reached in cohort 2 with a median time to follow-
up of 11.5 months. The results compared favorably to the 38% ORR reported for single-agent 
bortezomib in the phase III APEX trial [137].  
Amidst carfilzomib’s clinical development Proteolix was acquired by Onyx Pharmaceuticals 
in late 2009 with large payments contingent upon the expected FDA approval of carfilzomib. 
Onyx sought FDA accelerated approval for carfilzomib (trade name Kyprolis®) for the 
treatment of relapsed and refractory MM in 2012 based upon phase II efficacy data. Onyx 
additionally presented safety data from a total of 768 patients treated in phase I and II 
studies. Serious adverse events probably related to carfilzomib treatment were rare with the 
most common being pneumonia in 4% of patients and congestive heart failure in 3% of 
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patients. On July 20th, 2012, Carfilzomib was granted accelerated FDA approval with an 
ongoing phase III ASPIRE trial to confirm the drug’s clinical benefit and safety [108]. 
The randomized phase III ASPIRE trial (PX-171-009) examined carfilzomib in combination 
with the immunomodulatory agent lenalidomide and high-dose dexamethasone versus Len 
and high-dose Dex alone. ASPIRE enrolled 729 patients with relapsed MM who had received 
one to three prior therapies. Patients previously treated with bortezomib were eligible for 
the trial as long as they did not experience disease progression during bortezomib treatment. 
Progression-free survival was significantly greater in the carfilzomib group at 26.3 months 
versus 17.6 months in the control group. The ORR was 87% with carfilzomib and 67% 
without carfilzomib. Although median overall survival was not reached in either group, the 
24-month overall survival was significantly higher in the carfilzomib group by 8.3 percentage 
points (p=0.04). Although the carfilzomib group experienced a greater rate of grade 3 or 
higher adverse events and a greater rate of serious adverse events, they experienced fewer 
deaths during or shortly after treatment, and reported higher quality of life. The ASPIRE trial 
thus established the safety and efficacy of carfilzomib in relapsed MM as part of a three-drug 
regimen [138]. 
More recently, the phase III trial ENDEAVOR trial directly compared carfilzomib plus 
dexamethasone versus bortezomib plus dexamethasone in patients with relapsed or 
refractory MM [139]. As per its prescribing information, bortezomib was dosed at 1.3 mg/m3 
on days 1, 4, 8, and 11 per 28-day cycle. Based on new clinical data supporting the safety of 
higher doses of carfilzomib when given as a slow infusion, carfilzomib was dosed 20 mg/m3 
on the first cycle and 56 mg/m3 on subsequent cycles as a 30-minute infusion. The median 
PFS in the carfilzomib group was 18.7 months, a significant increase relative to the 
bortezomib groups median PFS of 9.4 months (p<0.0001). Interim data suggests that this 
larger difference in progression-free survival is present regardless of patients’ prior exposure 
to bortezomib. Median duration of response in the carfilzomib group was more than double 
that of the bortezomib group (21.3 vs. 10.4 months). Although patients treated with 
carfilzomib experienced a greater rate of grade 3 or higher adverse events, they experienced 
significantly fewer grade 2 or higher events of peripheral neuropathy, a known serious side 
effect of bortezomib treatment. While cardiac failure was more common in carfilzomib-
treated patients, a sub-study using serial echocardiograms found no evidence of cumulative 
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cardiac injury or ventricular dysfunction in the carfilzomib group. An interim analysis of 
overall survival for ENDEAVOR was published in Lancet Oncology in October 2017. The OS of 
carfilzomib-treated patients was significantly longer than that of bortezomib-treated patients 
(47.6 vs. 40.0 months, p=0.010) [140]. Taken as a whole, these results identify a significant 
efficacy gap between these two drugs in favor of carfilzomib and establish carfilzomib as a 
standard of care in the treatment of relapsed or refractory multiple myeloma.   
 
 Ixazomib 
A third proteasome inhibitor, ixazomib, was approved for clinical use by the FDA in 2015 
under the brand name Ninlaro® for the treatment of relapsed multiple myeloma. Ninlaro® is 
the first orally-administered proteasome inhibitor to reach the market. Structurally, ixazomib 
is an N-capped dipeptide boronic acid whose boronic acid pharmacophore can be esterified 
with citric acid to form the prodrug ixazomib citrate. Ixazomib itself is a potent inhibitor of 
the proteasome’s β5 and, to a lesser extent, β1 catalytic subunits (IC50 = 3.4 nM and 31 nM). 
Like bortezomib, ixazomib is a slowly-reversible inhibitor of the proteasome, but its 
dissociation rate is significantly faster (t1/2 = 110 and 18 minutes). Ixazomib citrate is 
reported to be immediately hydrolyzed to yield ixazomib upon exposure to aqueous solutions 
or plasma. Preclinical studies showed that ixazomib citrate had good oral bioavailability in 
mice and produced proteasome inhibition in blood cells and in tumor cells following i.v. 
administration. Twice-weekly oral doses of ixazomib citrate were shown to significantly 
reduce tumor volume in a mouse xenograft model of prostate cancer. When injected, 
ixazomib citrate was more efficacious than bortezomib in two preclinical models of 
lymphoma [81]. Notably, i.v. ixazomib had a better ratio of tumor:blood proteasome 
inhibition than bortezomib, suggesting that ixazomib has good distribution in tumor tissues. 
In humans, ixazomib citrate has oral bioavailability of 58% and has a terminal half-life of 9.5 
days allowing for once-weekly dosing. Ixazomib citrate was approved based on a double-
blind phase 3 trial of 722 multiple myeloma patients of ixazomib, lenalidomide, and 
dexamethasone versus Len and Dex only. Patients received 5.7 mg of ixazomib citrate which 
is equivalent to 4 mg ixazomib once per week for three weeks per 28-day cycle. ORR was 78% 
for ixazomib versus 72% for control, with the rate of VGRP at 48% and 39%, respectively. 
Notably the median time of PFS was 20.6 months in the ixazomib group versus 14.7% in the 
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control group. It should be noted that, as with bortezomib, patients taking ixazomib had a 
higher rate of peripheral neuropathy as compared to control (27% versus 22%) but the rate 
of grade 3 peripheral neuropathy was low at 2% [141].  
 
1.7 Unmet Clinical Needs and Drawbacks of Approved Inhibitors 
From the first clinical trials of bortezomib over 15 years ago to today, proteasome inhibitors 
have significantly changed the way that multiple myeloma is treated and have had a 
tremendous impact on patient survival and well-being. Despite this, there is still room for 
improvement. To date, proteasome inhibitors are FDA-approved only for the treatment of 
multiple myeloma and mantle cell lymphoma, diseases which represent less than 3% of new 
cancer cases in the US [142, 143]. Additionally, currently-approved proteasome inhibitors 
have several drawbacks such as undesired adverse events, susceptibility to drug resistance, 
and less than ideal pharmacokinetic properties. Efforts to develop proteasome inhibitors 
having strong activity in solid tumors or which avoid the drawbacks of existing inhibitors 
could help many more patients.  
 
 Clinical Trial Results in Non-Myeloma Cancers 
While proteasome inhibitors have played a significant role in improving patient outcomes in 
MM, they have seen little success in treating other types of cancer. Although bortezomib is 
approved for use in mantle cell lymphoma, their use in general is largely restricted to MM. 
During the preclinical development of bortezomib, it was clear that it had potent activity in a 
wide variety of cancer cell lines and bortezomib’s average growth inhibitory potency (GI50) 
in the NCI’s 60 cell line panel was excellent at just 7 nM. Furthermore, cell lines which were 
highly sensitive to bortezomib originated from a variety of cancer types including leukemia, 
colon cancer, melanoma, and renal cancer. Bortezomib also demonstrates cytotoxic activity 
in mouse models of a number of different cancer types including prostate cancer, colon 
cancer, melanoma, and adult T-cell leukemia, among others [125, 144-146]. Despite these 
signs of activity against a variety of non-myeloma cancers, many of the clinical trials of 
proteasome inhibitors in patients with these cancers have been relatively unsuccessful.  
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A phase I study of bortezomib and gemcitabine in 31 patients with advanced solid tumors 
identified only one patient with an objective response and seven patients with stable disease 
following treatment. Although the treatment’s observed toxicities were considered to be 
manageable, the MTD for bortezomib in this study was 1.0 mg/m3, lower than in MM patients 
[147]. A phase I/II study of bortezomib and docetaxel in 83 patients with androgen-
independent prostate cancer demonstrated that this combination was well tolerated with no 
dose-limiting toxicities at doses up to 1.6 mg/m3. However according to the study authors, 
the bortezomib/docetaxel combination therapy showed anti-tumor activity similar to that 
expected for docetaxel monotherapy. Among the 45 patients evaluable according to RECIST 
criteria, three patients had a confirmed partial response and no patients had a complete 
response [148].  A phase II study of single-agent bortezomib in 25 patients with advanced 
urothelial carcinoma identified no objective responses [149]. A phase II clinical trial of single-
agent bortezomib in 29 patients with advanced biliary tract cancers also identified no 
confirmed partial or complete responses [150]. As for hematologic cancers other than MM, a 
phase II study of bortezomib in patients with adult T-cell leukemia or lymphoma was 
published in 2015. A partial remission was observed in 1 of 15 patients and the authors 
concluded that bortezomib’s activity was not very promising in this population [151]. While 
there have been clinical trials in which bortezomib exhibited more promising activity in solid 
tumors, none have warranted the undertaking of a large-scale phase III trial to compare a 
proteasome inhibitor to the current best-in-class therapies for these diseases.  
As with bortezomib, there is data which suggests that carfilzomib has preclinical activity in 
cancers besides MM such as lung cancer and colon cancer [152, 153]. Although carfilzomib 
was first tested in humans much more recently than bortezomib, data from a phase I/II trial 
of carfilzomib in patients with advanced solid tumors has been published. Among the 12 
evaluable patients in the phase I dose-escalation study, two patients had confirmed partial 
responses and two patients had stable disease [154]. Of the 51 evaluable patients in the phase 
II dose expansion study, no patients achieved a partial response or better after four or more 
cycles of carfilzomib therapy and 11 patients had stable disease after four or more cycles of 
therapy. Although there is relatively little available data to examine the efficacy of carfilzomib 
in solid tumors, the lack of large scale clinical trials of carfilzomib in non-myeloma cancers is 
telling in it of itself.  
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One phase I dose-escalation and dose-expansion study of IV ixazomib in patients with 
advanced non-hematologic cancer has been published [155]. Among 92 evaluable patients 
who received at least one cycle of ixazomib, one patient with head and neck cancer achieved 
a partial response. 30 patients achieved stable disease with 8 of those patients maintaining 
stable disease for at least 4 cycles. The study authors noted that the antitumor activity of 
ixazomib was limited and was comparable to observations of bortezomib’s and carfilzomib’s 
lack of activity in patients with advanced solid tumors.  
Overall, the poor activity of currently-approved proteasome inhibitors in non-myeloma 
cancers is disappointing considering their highly promising preclinical activity. Considering 
the significant positive impact of proteasome inhibitors on the multiple myeloma treatment 
landscape, efforts to understand the poor efficacy of bortezomib, carfilzomib, and ixazomib 
in patients with solid cancers are laudable.   
 
 Adverse Event Profiles of Approved Proteasome Inhibitors 
The FDA-approved proteasome inhibitors bortezomib, carfilzomib, and ixazomib share a 
number of adverse events which may or may not be intrinsic properties of 
proteasome-inhibiting drugs. Adverse event (AE) data collected from clinical trials indicates 
that gastrointestinal AEs such as diarrhea, constipation, and vomiting are commonly reported 
(>20% incidence) with all three drugs. Nausea and fatigue are also commonly reported 
during treatment with these three proteasome inhibitors. While these AEs are very common, 
their severity is typically low. Thrombocytopenia, a reduction in platelet count, is also 
commonly reported for all three drugs but was more frequently severe or life-threatening 
(grade 3/4) with incidence rates of 15%, 24%, and 26% for carfilzomib, bortezomib, and 
ixazomib, respectively. Research on the effects of bortezomib on platelet function indicate 
that bortezomib transiently reduces platelet production by megakaryocytes but does not 
decrease the lifespan of circulating platelets [156].  
In addition to these common adverse events, each drug has undesired effects which are 
specific to that drug and could be related to off-target activity. In clinical trial data 
encompassing 663 patients, 35% of patients treated with single-agent bortezomib 
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experienced peripheral neuropathy versus 4% of patients treated with dexamethasone. The 
rate of grade 3 and 4 peripheral neuropathy in these groups was 7.6% and 0.3%, respectively. 
The propensity of bortezomib to cause peripheral neuropathy frequently leads to dose 
modification and impacts patient quality of life [157]. In contrast to bortezomib, the rate of 
peripheral neuropathy in patients treated with a carfilzomib-containing regimen was only 
11%, one percentage point above the incidence rate in the control group. Patients treated 
with ixazomib also experienced a relatively low rate of peripheral neuropathy at 28% versus 
21% in the control group. Only 2% of patients treated with ixazomib experienced grade 3 or 
higher peripheral neuropathy. According to research published by Arastu-Kapur et al., 
bortezomib’s inhibition of the neuronal serine protease HtrA2/Omi may be responsible for 
the high incidence of this adverse event. This research found that bortezomib was capable of 
potently inhibiting several serine proteases such as cathepsin G and chymase. Using a 
database mining approach, HtrA2/Omi was identified as a protease which was both likely to 
be inhibited by bortezomib and played a key role in neuronal function. Further investigation 
revealed that bortezomib but not carfilzomib inhibited HtrA2/Omi with a low nanomolar IC50 
[158]. Considering its key role in neuronal survival and function, bortezomib’s off-target 
inhibition of HtrA2/Omi may be the key cause of bortezomib-induced peripheral neuropathy. 
Carfilzomib treatment has been associated with cardiovascular adverse events including new 
or worsening cardiac failure and myocardial infarction. In a randomized trial of carfilzomib 
plus lenalidomide and dexamethasone versus Len and Dex alone the rate of cardiac failure 
events was 6.4% and 4.1%, respectively among 781 total patients [138]. In a randomized trial 
of carfilzomib plus Dex versus bortezomib plus Dex, the rate of cardiac failure events was 8% 
and 3%, respectively. Higher than expected incidences of renal insufficiency and acute renal 
failure have also been reported in patients treated with carfilzomib. Although the mechanism 
by which carfilzomib impacts cardiac function is still unknown, the topoisomerase-II 
inhibitor and iron chelating agent dexrazoxane has been reported to protect mice from 
carfilzomib-induced cardiotoxicity, potentially via a reduction in reactive oxygen species 
(ROS).  
Currently available safety data from patients treated with ixazomib has not shown high rates 
of cardiac adverse events or of serious peripheral neuropathy. While patients treated with 
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ixazomib did experience an increased incidence of eye disorders as compared to control 
(26% versus 16%), the vast majority of these adverse reactions were not severe [159].  
Although additional research is needed to determine the underlying causes of these adverse 
events, the development of novel proteasome inhibitors which avoid some of these agent-
specific adverse events such as peripheral neuropathy or cardiotoxicity could reduce the 
number of patients who are forced to discontinue PI therapy due to these undesired drug 
reactions. 
 
 Resistance to Proteasome Inhibitors  
Resistance to proteasome inhibitor therapies represents a significant impediment to their 
effectiveness in the treatment of cancer. While proteasome inhibitors have strong anti-
myeloma activity, especially when combined with other agents, they remain ultimately 
incapable of curing MM due in large part to the emergence of drug resistance. In clinical 
practice, a significant fraction of patients do not respond to PI therapy and many other 
patients who do initially respond will experience relapse during therapy. While some 
mechanisms of drug resistance are likely to be unique to individual PI drugs, evidence of 
cross-resistance between the peptide-based inhibitors bortezomib and carfilzomib has been 
observed. Based on data from the phase II PX-171-003 trial of carfilzomib in bortezomib-
treated patients, carfilzomib exhibits reduced activity in this patient group as compared to 
bortezomib-naïve patients [160]. While this difference could reflect the more advanced state 
of disease in these patients, it may also indicate the development of cross-resistance in 
bortezomib-treated patients. In order to better understand the potential mechanisms of 
proteasome inhibitor resistance in patients, significant preclinical research has been 
undertaken. Though the exact mechanisms of clinical PI resistance remain largely unknown, 
preclinical studies have revealed several likely candidates. The phenomenon of PI resistance 
has been studied both in models of multiple myeloma as well in solid cancers, thus these 
mechanisms may explain the poor activity of current PI’s in patients bearing solid tumors as 
well as observed PI resistance in MM patients. Such mechanisms include overexpression or 
mutation of proteasome catalytic subunits, increased drug efflux from cells, altered 
proteasome activity and expression, and alterations in the unfolded protein response (UPR).  
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 Resistance via Overexpression or Mutation of Proteasome Subunits 
Overexpression of the PSMB5 gene which encodes the proteasome β5 catalytic subunit have 
been reported in several preclinical models of proteasome inhibitor resistance. A 2008 report 
by Lu et al. investigated the characteristics of a bortezomib-resistant Jurkat cell line 
developed by over 6 months of continuous exposure to bortezomib. This highly-resistant 
JurkatB5 line overexpressed PSMB5 at the mRNA level. Total chymotrypsin-like activity was 
increased, suggesting increased protein levels of active β5. Amplification of the PSMB5 gene 
was also detected [161]. Another 2008 report by Oerlemans et al. examined several THP-1 
cell lines which acquired bortezomib resistance via long-term continuous exposure. The 
THP-1/Btz100 cell line exhibited a 79-fold increase in the IC50 value for bortezomib 
cytotoxicity but no significant cross-resistance to a panel of other chemotherapeutic agents. 
The THP-1/Btz100 cell line did, however, have significant cross-resistance to several other 
proteasome-targeting peptide aldehydes. Cross-resistance was especially marked in the case 
of 4A6, a cytotoxic peptide believed to specifically target the β5 subunit. The β5 catalytic 
subunit was highly overexpressed in these resistant cell lines and siRNA-mediated silencing 
of PSMB5 led to a significant restoration of bortezomib sensitivity. Additionally, an Ala49Thr 
mutation in the β5 catalytic subunit protein was identified in highly-resistant THP-1 cells 
[162]. Ala49 is positioned in the S1 binding pocket, a key factor in determining the β5 
catalytic subunit’s interactions with inhibitors [34, 80]. Additional studies have confirmed 
the existence of the β5 Ala49Thr mutation in other bortezomib-resistant cell lines as well as 
several other mutations such as Ala50Val, Cys52Phe, and Met45Ile, all of which occur in or 
near the S1 binding pocket and may be hypothesized to interfere with bortezomib’s ability to 
bind to the subunit. Using yeast proteasomes with engineered mutations to their catalytic 
subunits, Huber et al. demonstrated that mutations to Ala49, Met45, and Cys52 can reduce 
the ability of bortezomib and carfilzomib to inhibit their catalytic activity, by over 20-fold in 
some cases [163]. Considering that the β5 subunit is the key target of bortezomib and most 
cytotoxic proteasome inhibitors, we can also hypothesize that the mutations in the PSMB5 
gene which reduce proteasome inhibitor binding affinity without significantly affecting 
normal catalytic activity may protect the cell from proteasome inhibitors. Notably, an 
inhibitor which targets the non-catalytic α7 proteasome subunit retains full activity in 
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bortezomib-resistant THP-1 cells which overexpress mutated PSMB5 [164]. This suggests 
that these cells remain fully reliant on proteasome function for cell survival. Although one 
case study has identified PSMB5 mutations in a single bortezomib-treated patient, several 
other larger scale studies have failed to do so, suggesting that PSMB5 mutations may not play 
a significant role in clinical resistance to bortezomib [165-167].  
 
 Resistance via Increased Drug Efflux 
A 2012 publication by Verbrugge et al. examined the impact of a number of drug efflux 
transporters on sensitivity to four proteasome inhibitors using cell line models. The most 
notable result was with the CEM/VLB cell line which overexpressed P-glycoprotein (P-gp, 
also known as MDR1). This cell line had only a modest resistance to bortezomib relative to a 
control cell line (4.5-fold), but was highly resistant to the three epoxyketone inhibitors tested. 
The resistance factors were 114-fold, 23-fold, and 162-fold for carfilzomib, ONX 0912, and 
ONX 0914, respectively. Cell lines overexpressing the MRP1 through MRP5 or BCRP 
transporters did not have greater than 2.5-fold increased sensitivity to any of the proteasome 
inhibitors tested. In CEM/VLB, co-treatment with a peptide inhibitor of P-gp greatly reduced 
resistance to all three epoxyketone PI’s [168]. A publication from our group confirmed these 
findings by identifying increased P-gp expression in H23 and DLD-1 cell lines which had 
acquired carfilzomib resistance. Treatment with verapamil, a known P-gp inhibitor, restored 
sensitivity to near that of the parental cell lines [169]. In a recent publication by Besse et al., 
MM cells were isolated from patients first during their initial response to carfilzomib therapy 
and then later during consecutive disease progression under carfilzomib therapy. Evaluating 
these samples for paired gene expression identified significant increases in the expression of 
the ABCB1 (P-glycoprotein) gene. Deletion of the ABCB1 gene by CRISPR/Cas9 editing in 
carfilzomib-resistant AMO cells resulted in an 8-fold increase in carfilzomib sensitivity as 
well as a 7-fold increase in sensitivity to the epoxyketone PI oprozomib. Patients newly-
diagnosed with plasma cell leukemia (PCL), an aggressive form of MM, were also found to 
overexpress ABCB1 within circulating plasma cells. Overexpression of P-glycoprotein in the 
carfilzomib-resistant AMO cell line model directly resulted in increased carfilzomib efflux and 
decreased proteasome inhibition [170]. Additionally there is evidence to suggest that P-gp 
plays a role in resistance to other anti-myeloma agents such as vincristine and doxorubicin, 
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and that P-gp expression is likely to be increased in patients who have been treated with 
these agents [171, 172].  
 Resistance via Altered Proteasome Activity and Expression 
As discussed previously, increased expression of the β5 catalytic subunit targeted by 
bortezomib and carfilzomib is a mechanism of drug resistance in preclinical models. 
Additionally, more complex changes in the expression and activity levels of the six 
proteasome and immunoproteasome catalytic subunits have been observed in cell line 
models of proteasome inhibitor resistance. In a 2011 publication Suzuki et al. examined the 
expression levels of all six catalytic subunits in HT-29 cells with acquired bortezomib 
resistance. After 14 days of withdrawal from bortezomib these cells maintained a 28-fold 
bortezomib resistance factor and when compared to parental cells had significantly increased 
expression of five catalytic subunits: β1, β2, β5, β1i, and β5i. Measurements with fluorogenic 
peptide substrates confirmed increased catalytic activity of the CT-L, T-L, and C-L activities. 
Interestingly, despite the fact that the β1 and β2 subunits are not potently inhibited by 
bortezomib, their expression was increased to a similar degree as β5. Additionally the β5i 
subunit showed the highest-fold upregulation, over five times greater than the low-level 
expression observed in parental HT-29 cells [173]. Measurements of catalytic subunit protein 
expression levels in the bortezomib-resistant THP-1 cell line by Verbrugge et al. also 
identified altered expression of multiple subunits, however the specific pattern was different. 
In this case, while β1, β2, β5 protein levels were upregulated (approx. 2-fold), β1i was 
significantly downregulated and β2i and β5i were not significantly altered. Looking 
specifically at cell lines of hematologic origin, Niewerth et al. generated bortezomib-resistant 
sub-lines of RPMI-8226, THP-1, and CCRF-CEM which exhibited bortezomib resistance 
factors of 40- to 150-fold [174]. Sequencing of the PSMB5 gene revealed that all three 
resistant cell lines carried the Ala49Thr mutation. As compared to their parental 
counterparts, the resistant THP-1 and CEM cell lines showed an overall increase in 
proteasome content and increases in the relative proportions of the β1, β2, and β5 subunits 
in the overall pool of catalytic subunits. In contrast, RPMI-8226 only experienced minor 
increases in overall proteasome content and relative β1/β2/β5 content, but this may be due 
to its higher basal levels of constitutive proteasome expression. Treating these three resistant 
cell lines with IFN-γ lead to the upregulation of the β1i and β5i subunits at the mRNA and 
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protein levels as well as moderate decreases in constitutive catalytic subunit expression 
levels. A corresponding decrease in C-L activity and increases in β5i-specific and β1i-specific 
catalytic activities were observed. These alterations were significantly more pronounced 
than in parental cells treated with IFN-γ. Treatment with IFN-γ significantly restored 
bortezomib sensitivity in all three cell lines. Notably, siRNA-mediated silencing of β5i blocked 
this effect but β1i silencing did not. Niewerth et al. hypothesized that downregulation of β5i 
may be a determinant of bortezomib resistance and that IFN-γ-mediated upregulation of β5i 
may drive the assembly of immunoproteasomes or may facilitate the generation of hybrid 
proteasomes which combine β5i with constitutive catalytic subunits. Whether this 
relationship between β5i expression and bortezomib resistance is due simply to the 
displacement of mutated β5 from proteasomes, or whether β5i-containing proteasomes have 
an intrinsic resistance to the effects of bortezomib is unknown [174]. Further research has 
also indicated that the relative expression levels of proteasome and immunoproteasome 
catalytic subunits may be predictive of response in some patients with acute leukemia [175, 
176]. While overall it is clear that alterations in expression and activity levels of proteasome 
catalytic subunits is a feature in several cell line models of acquired resistance, the magnitude 
of the clinical relevance of this fact is still unknown.  
 
 Resistance via the Unfolded Protein Response 
Recent research has highlighted alterations in the unfolded protein response (URP) as a 
potential non-proteasomal mediator of resistance to proteasome inhibitors. The UPR is a 
stress response pathway which is activated following the accumulation of unfolded or 
improperly folded proteins within the endoplasmic reticulum (ER). UPR activation can have 
a protective effect via the downregulation of protein synthesis and upregulation of pathways 
which aid in protein folding and protein degradation. Alternatively, UPR activation can 
activate apoptosis leading to cell death under certain circumstances. The UPR consists of 
three major signaling arms, the PERK arm, the ATF6 arm, and the IRE1 arm. The IRE1 arm is 
of particular interest in this context. IRE1 is an endoplasmic reticulum (ER) transmembrane 
protein which has a luminal domain which senses ER stress and a cytoplasmic RNase domain 
which initiates downstream signaling via the splicing of XBP1 mRNA to yield the XBP1s 
mRNA. This mRNA is then transcribed to yield XBP1s protein, a bZIP family transcription 
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factor which acts on a number of target genes [177].  Although it has been known for some 
time that PI’s can both induce the UPR and inhibit Xbp1s signaling, the role of the UPR and 
IRE1/XBP1s specifically in proteasome inhibitor resistance was not explored in detail until 
more recently [178]. In 2011 Zhu et al. reported the results of an RNAi screen of the druggable 
genome which sought genes which would sensitize KMS11 myeloma cells to bortezomib 
when silenced. Upon reanalyzing this data in search of compounds which had an opposite 
protective effect, the IRE1 gene was identified as a top candidate [179]. This was a surprising 
finding considering that IRE1 signaling was thought to help restore homeostasis in the face 
of ER stress. As the XBP1 gene was not tested in the original screen, additional experiments 
were performed which revealed that XBP1 silencing also induced bortezomib resistance in 
six different MM cell lines. Using gene expression data from a phase III trial of bortezomib the 
authors found a correlation between downregulation of the IRE1-XBP1 signaling pathway 
and poor clinical response to bortezomib. Further studies identified the presence of Xbp1s- 
pre-plasmablasts in primary MM samples which are intrinsically insensitive to bortezomib 
and which become enriched following PI therapy. As with MM cells which have been XBP1-
silenced, these XBP1s- plasmablasts exhibit reduced immunoglobulin secretion suggesting 
that these cells are less sensitive to ER stress and accordingly less sensitive to proteasome 
inhibition due to a reduced basal ER load. This hypothesis has gained additional credence 
with the finding that high XBP1 expression is a prognostic indicator of better outcome in MM 
patients treated with bortezomib [180]. While XBP1s may play a significant role in the 
sensitivity to MM to proteasome inhibitors, it is unlikely to play a role in the sensitivity or 
resistance of other cancer types to PI considering the interaction between XBP1s function 
and plasma cell maturation and immunoglobulin secretion.  
 Overall, these potential mechanisms of a resistance still require significant clinical 
validation to determine their relevance in the clinic both for the treatment of MM with 
proteasome inhibitors as well as for the potential application of proteasome inhibitor in non-
myeloma cancers. Nonetheless there may be the potential to develop novel proteasome 
inhibitors which lack cross-resistance to existing FDA-approved PI’s, or which have activity 
in intrinsically insensitive cancer types due to their novel properties.  
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 Pharmacokinetic Properties of Approved Proteasome Inhibitors 
Although bortezomib, carfilzomib, and ixazomib are effective in the treatment of myeloma, 
they have pharmacokinetic (PK) properties which may negatively impact their activity in 
solid tumors. Though bortezomib, carfilzomib, and ixazomib are known to be active in a 
number of xenograft models of solid tumors, there are important differences between these 
models and solid tumors found in human patients. As compared to human solid tumors, 
mouse xenograft tumors are significantly different in terms of tumor-immune system 
interaction and in terms of tumor microenvironment and tumor architecture [181]. These 
differences can significantly alter drug function leading to cases where drugs are significantly 
more or less effective in human patients than would be expected based on mouse xenograft 
models. Although there has been research into the pharmacokinetic properties of 
bortezomib, carfilzomib, and ixazomib in both humans and animals, very little of it has 
focused on the behavior of the drug within solid tumors in particular. What research is 
available and the overall pharmacokinetic properties of these drugs will be discussed below.  
Bortezomib is a slowly-reversible proteasome inhibitor with an in vivo half-life of 76-108 
hours at the standard 1.3 mg/m3 dose. Bortezomib’s volume of distribution is large (498 to 
1884 L/m²), potentially indicating good distribution to peripheral tissues [182]. Plasma 
bortezomib concentrations peaked at 223 ng/mL (580 nM) following i.v. administration of 
1.3 mg/m3 bortezomib with average plasma concentrations dropping below 10 ng/mL (26 
nM) by one hour post-dose. Peak inhibition of blood CT-L (chmyotrpysin-like) proteasome 
activity following 1.3 mg/m3 of i.v. bortezomib was 69.3% on average with inhibition levels 
falling to approximately 45% and 25% at 6 and 24 hours post-dose, respectively [183]. It 
should be noted that high apparent volume of distribution is reflective of rapid clearance of 
bortezomib in systemic circulation, but not necessarily an indication of drug distribution to 
various organs including solid tumor tissues. The major elimination route of bortezomib is 
via oxidative deboronation catalyzed by P450 enzymes found predominantly in the liver 
[184, 185]. This reaction yields two stereoisomeric carbinolamide metabolites which lack the 
boronic acid pharmacophore required for covalent inhibition of the proteasome.  
A publication by Clemens et al. identified massive intracellular accumulation of bortezomib 
in nine different multiple myeloma cell lines which appeared to be independent of influx 
transporter activity [186]. Following incubation with 1 nM bortezomib, intracellular drug 
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concentration rose rapidly in the first four hours and remained elevated until 48 hours post-
dose while extracellular concentrations gradually declined. After one hour the intracellular 
bortezomib concentration was 43-fold higher than the extracellular concentration on 
average. The peak intracellular concentration of bortezomib differed significantly between 
cell lines but the median concentration was 271 nM giving an intracellular/extracellular 
concentration ratio of well over 1000-fold. Incubating cells with 5 nM or 25 nM of bortezomib 
yielded even higher peak intracellular concentrations, however the increase was less than 
proportional (2.9x and 4.8x relative to 1 nM). Although the mechanism of this significant drug 
accumulation was not determined, bortezomib’s high-affinity binding to the proteasome was 
proposed by the authors as one potential factor. If intracellular bortezomib accumulation 
occurs in other cell types found in the body, it could impact bortezomib’s ability to reach solid 
tumor cells.  
It should also be noted that the architecture of solid tumors itself can impair drug distribution 
[187]. Cancer cells within tumors may grow more rapidly than the blood vessels which supply 
them leading to poor vascularization and giving rise to cells which are isolated from blood 
vessels creating a hypoxic environment. When combined with increased glycolysis due to the 
Warburg effect, tumor pH is decreased as well. Solid tumors may also suffer from high 
interstitial fluid pressure and a lack of lymphatic flow. These factors can lead to low drug 
concentrations in significant portions of the tumor.  
A 2009 paper published by researchers at Millennium Pharmaceuticals remarked that 
bortezomib exposure and pharmacodynamic profiles varied across different tumor xenograft 
models [188]. As such they sought to study bortezomib’s efficacy in two xenograft models 
with a known disparity in bortezomib sensitivity, CWR22 and H460. Both cell lines are 
sensitive to bortezomib in vitro with IC50’s of 4.0 and 7.4 nM, respectively, in a 48-hour cell 
viability assay. Next they studied the effects of twice-weekly i.v. bortezomib in nude mice 
bearing CWR22 or H460 tumors. Peak bortezomib concentrations (Cmax) and AUC0-48h values 
measured in blood were similar in both groups with the H460 group having a 7.9% higher 
Cmax and a 1.6% higher AUC0-48h as compared to the CWR22 group. In contrast, the intra-
tumoral concentration of bortezomib differed greatly between the two groups. Peak tumor 
bortezomib concentration was 4.8-fold higher and bortezomib AUC0-48h was 3.1-fold higher 
within CWR22 xenograft tumors than H460 tumors. Peak inhibition of tumor β5-specific 
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proteasome activity was approximately 40% in the CWR22 group but was less than 10% in 
the H460 group. Using average tumor volume reduction as a marker of drug efficacy, 
bortezomib treatment significantly reduced tumor volume CWR22-bearing mice but not in 
H460-bearing mice. Dynamic contrast-enhanced MRI was used to measure the distribution 
of a contrast-agent into the core of CWR22 and H460 tumors which found significantly 
reduced signal in H460 tumors. Micro computed tomography (MicroCT) vascular casting 
confirmed that H460 tumors were poorly vascularized in their core regions as compared to 
CWR22 tumors. The authors concluded that prominent differences in tumor vasculature and 
architecture may result in reduced tumor concentrations of bortezomib and consequently 
reduced bortezomib efficacy in poorly vascularized tumors. Whether these results translate 
to human solid tumors is yet unknown. 
In contrast to bortezomib or ixazomib, carfilzomib is rapidly eliminated from the body. In a 
study of three solid tumor patients dosed with 20 mg/m3 carfilzomib via a short i.v. infusion, 
an average peak plasma drug concentration of 2,760 ng/mL (3,830 nM) was achieved 
immediately after dosing [189]. Plasma carfilzomib concentrations declined rapidly 
thereafter with a half-life of 1.0 ± 0.6 hours (mean ± S.D.). At four hours post-dose the average 
plasma concentration of carfilzomib was below 0.2 ng/mL (<0.3 nM). Average plasma 
clearance of carfilzomib exceeded typical hepatic blood flow, suggesting the involvement of 
extrahepatic clearance mechanisms [190]. Analysis of patient plasma samples identified 
three major metabolites, M14, M15, and M16. Metabolites M14 and M15 are N-terminal 
fragments of carfilzomib which are formed via peptide bond hydrolysis of carfilzomib at the 
P3-P4 and P2-P3 peptide bonds, respectively. M16 is the diol of carfilzomib formed via 
epoxide ring opening. These metabolites are believed to be formed by the actions of 
peptidase(s) and epoxide hydrolase(s). In contrast, metabolites formed via P450 enzymes 
were only detected at very low levels. An in vitro study using rat tissue homogenates has 
confirmed that carfilzomib metabolism is not restricted to the liver and that lung, kidney, and 
heart tissues all possess the ability to rapidly degrade carfilzomib to its inactive metabolites 
[191]. Although carfilzomib is metabolized rapidly, it achieves a prolonged 
pharmacodynamic response via its irreversible covalent binding to the proteasome. In 
RPMI-8226 and HT-29 cell lines treated with a one-hour pulse of 32 nM bortezomib or 
carfilzomib, the degree of inhibition of proteasomal CT-L activity after 24 or 72 hours was 
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equal or greater in cells treated with carfilzomib as compared to bortezomib [133]. In BALB/c 
mice treated with 1 mg/kg bortezomib or 5 mg/kg carfilzomib, blood CT-L inhibition (approx. 
90%) was similar in both groups after one hour. Differences in tissue CT-L inhibition between 
two groups at one hour post-dose were minor. Recovery of whole blood CT-L activity was 
much faster in bortezomib-treated mice, returning to 100% of control at +72 hours. In 
contrast, whole-blood CT-L activity was still below 25% of control at +72 hours in 
carfilzomib-treated mice. Proteasomal CT-L activity also recovered more quickly with 
bortezomib in heart tissue when measured at +24 hours. Interestingly, in rats dosed with 8 
mg/kg i.v. carfizomib, ≥90% inhibition of proteasome CT-L activity was observed in heart, 
lung, and adrenal tissues at 2 hours post-dose. However liver CT-L activity was inhibited to a 
lesser degree, approximately 70%, despite prior confirmation that carfilzomib is well-
distributed to the liver [133]. The authors suggest that competition between the proteasome 
and carfilzomib-metabolizing enzymes may reduce its activity in the liver. This suggests that 
tissues which express high levels of carfilzomib-metabolizing enzymes may be more resistant 
to its effects.  
As described previously, ixazomib is a reversible proteasome inhibitor which dissociates 
from the proteasome more rapidly than bortezomib. The pharmacokinetics of 2 mg/m3 oral 
ixazomib (as ixazomib citrate) were evaluated in 31 patients with multiple myeloma [192]. 
On average, a peak drug plasma concentration of 49 ng/mL (136 nM) was achieved at 0.65 
hours after dosing on day 1. The terminal half-life was evaluated following the third dose 
(cycle 1 day 11) and was found to be 116 hours, slightly longer than that of bortezomib. Due 
to its long elimination half-life, significant inter-dose accumulation of ixazomib was already 
observed by cycle 1 day 11 where an accumulation ratio of 3.09 was calculated.  Although 
there is, as yet, relatively little data concerning ixazomib’s pharmacodynamics in humans 
with solid tumors, a publication by Kupperman et al. provides extensive data comparing 
ixazomib and bortezomib in mouse models [81]. Ixazomib displayed a blood volume of 
distribution of 20.2 L/kg in mice, over four-fold greater than for bortezomib. Ixazomib’s 
effects were evaluated in mice bearing CWR22 human prostate xenograft tumors or WSU-
DLCL2 human lymphoma tumors. Both drugs were dosed intravenously at the MTD, however 
the MTD for ixazomib was determined to be much higher than for bortezomib (14 and 0.8 
mg/kg, respectively). Despite this discrepancy in dose, the peak inhibition of blood β5 activity 
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was slightly greater in animals treated with bortezomib. Of particular interest is the peak 
inhibition of tumor β5 activity which was much greater in ixazomib-treated mice. Specifically, 
bortezomib achieved peak inhibition levels of 44.8% and 27.6% in the CWR22 and 
WSU-DLCL2 groups, respectively, whereas ixazomib achieved levels of 69.1% and 77.0%, 
respectively. This relationship was mirrored when evaluating 0-24 hour area under the effect 
vs. time curve for proteasome inhibition (AUEC). Although the AUEC in blood was greater for 
bortezomib, tumor AUEC was much higher for ixazomib for both tumor types. Accordingly, 
the treatment to control ratios for tumor volume with ixazomib were slightly better than 
bortezomib in CWR22-bearing mice and much better in WSU-DLCL2-bearing mice. Although 
the concentration of ixazomib within the tumors was not measured, it is plausible that 
ixazomib’s ability to achieve greater pharmacodynamics effects in tumors without causing 
greater proteasome inhibition in blood may be due to an improved drug penetration and 
partitioning into solid tumors ratio as compared to bortezomib.  
In conclusion, we have evidence that tumor architecture can negatively impact bortezomib’s 
efficacy in mouse models of poorly vascularized solid tumors and that this effect is most likely 
due to poor partitioning of bortezomib into such tumors. There is also evidence that ixazomib 
achieves greater intratumoral proteasome inhibition in xenograft-bearing mice than 
bortezomib at their respective MTDs. Whether this difference is due to differences in 
proteasome binding kinetics, membrane permeability, susceptibility to drug transporters, or 
other factors is not yet known. In the case of carfilzomib, research indicates that carfilzomib 
can be rapidly metabolized to inactive compounds by a wide variety of bodily tissues and that 
tissues which metabolize carfilzomib more rapidly show decreased proteasome inhibition by 
carfilzomib. Whether these properties are a factor in carfilzomib’s poor activity in humans 
with solid tumors is unknown. At a fundamental level, we know that proteasome inhibitors 
must be well-distributed to tumor cells and must reach their targets before being 
metabolized in order to exert a therapeutic effect.  
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1.8 Non-Peptide and Non-Covalent Proteasome Inhibitors  
As discussed above, proteasome inhibitors have proven activity against a variety of solid 
cancer cell lines and against preclinical animal models of solid cancers. Unfortunately, clinical 
trials of bortezomib and carfilzomib in patients with solid tumors have yielded disappointing 
results. The poor activity of these drugs in patients with solid tumors could be attributed to 
a number of factors such as insufficient maximum tolerated dose, poor drug penetration into 
solid tumors, high drug efflux from solid cancer cells, or the rapid acquisition of drug 
resistance via changes in proteasome catalytic subunit expression levels or other 
mechanisms. The discovery of structurally-novel proteasome inhibitors could alleviate these 
issues. The vast majority of existing proteasome inhibitors utilize a peptide backbone and a 
reactive C-terminal warhead, a simple recipe that tends to yield potent proteasome 
inhibitors. In contrast, the potential for non-peptide-based non-covalent inhibitors of the 
proteasome has gone largely unexplored. Prior research examining non-covalent inhibitors 
of the proteasome (either peptide-based or non-peptide-based) is recounted below.  
 
 Prior Discoveries in the Area of Non-Peptide Inhibitors 
Non-covalent proteasome inhibitors have long been sought after as a solution for the 
promiscuity of many types of reactive warheads such as aldehydes, vinyl sulfones, and 
boronic acids. An early report of non-covalent peptide inhibitors of the proteasome was 
published by Lum et al. in 1998. These compounds consisted of a hydrophobic dipeptide core 
which is N- and C-terminally capped with aromatic substituents. One of the compounds 
reported, CVT-600 consisted of a L-Leu-D-Leu dipeptide with a C-terminal aminobenzyl cap 
and a substituted indanone acetic acid cap at the N-terminus (Figure 1.9). At a concentration 
of 10 μg/mL (~18 μM), CVT-600 inhibited 20S proteasome chymotrypsin-like (CT-L) activity 
by >90% with minimal inhibition of proteasome T-L or C-L activities and with minimal 
inhibition of the non-proteasomal protease calpain I [193]. According to a second publication 
by Lum et al., an analogue of CVT-600 dubbed compound 28 bearing an altered C-terminal 
cap achieved a proteasome CT-L IC50 of 0.14 μM (Figure 1.9) [194]. For comparison, the CT-L 
IC50 of CVT-600 according to this publication was 0.93 μM. Although these compounds were 
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not directly proven to act as non-covalent inhibitors, their ability to retain inhibitory activity 
with a wide variety of C-terminal substituents suggests a non-covalent mechanism.  
Research into non-covalent proteasome inhibitors was further advanced with the discovery 
of the proteasome-inhibiting natural product TMC-95A produced by the fungus Apiospora 
montagnei. Reported by Koguchi et al. in 2000, TMC-95A is a macrocyclic peptide containing 
a biaryl junction between tyrosine and tryptophan side chains with a total molecular weight 
of 678.7 Da (Figure 1.9). It was found to be a potent inhibitor of 20S proteasome catalytic 
activities with IC50’s of 5.4, 60, and 200 nM against the CT-L, C-L, and T-L activities, 
respectively [195, 196]. Unlike all other previously known inhibitors, X-ray crystallographic 
analysis of TMC-95A in complex with yeast 20S proteasome found no covalent bond with the 
proteasome’s catalytic Thr1 residues but rather a network of hydrogen bonds between the 
inhibitor and proteasome catalytic subunit residues including Ser20, Thr21, Gly23, and 
Ala49. A hydrogen bond with Thr1Oγ was identified as well as hydrophobic interactions in 
the S1 and S3 specificity pockets which may drive the inhibitor’s specificity for CT-L activity 
[197]. 
Efforts by researchers at Millenium Pharmaceuticals have employed a more systematic 
approach to discover structurally-novel proteasome inhibitors. According to their 2010 
publication, they conducted an extensive screen of approximately 352,000 small molecule 
compounds using a cell-based assay in which a tetra-ubiquitin luciferase reporter 
accumulates following ubiquitin-proteasome system inhibition [113]. Of 611 confirmed hits, 
the majority were peptide boronic acids or E1 inhibitors with 191 previously unknown 
proteasome inhibitors. These active compounds were assayed for their ability to inhibit 
purified 20S proteasome using a fluorogenic β5-specific substrate (Ac-WLA-AMC). While 
most of the test compounds did not inhibit the 20S proteasome, a series of four N,C-di-capped 
tripeptides were identified as potent inhibitors of 20S proteasome β5 activity. Compound 1, 
utilizing a tri-homophenylalanine core, had IC50’s of 16 and 8.9 nM against 20S β5 and 20S 
β5i activity, respectively, and >1000x selectivity for β5/β5i over all over catalytic subunits 
(Figure 1.9). The results of kinetic analysis were consistent with non-covalent reversible 
binding. In the tetra-ubiquitin luciferase accumulation assay in MDA-231 cells, compound 1 
had a higher EC50 than bortezomib (690 vs. 240 nM) and a lower maximal induction (52- vs. 
340-fold). Compound 1 also displayed cytotoxic activity against a variety of cancer cell lines, 
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but with potencies on the order of 10-fold less than bortezomib. With assistance from an X-
ray crystallographic structure of compound 1 bound to yeast 20S proteasomes, compound 1 
was optimized to generate analogues with improved in vitro and cellular potency, most 
notably compound 16 with 20S β5 and β5i IC50’s of 1.2 and 1.1 nM, respectively, as well as 
greatly improved potency in all cell-based assays including cytotoxicity. Non-covalent 
inhibitors with >10x selectivity for β5 over β5i and vice versa were also described. In 
conclusion, this work demonstrated that peptide-based non-covalent inhibitors could 
achieve in vitro potencies within an order of magnitude of bortezomib, significantly better 
than previously reported compounds such as CVT-600 or TMC-95A. While the reported 
results are promising, the pharmacokinetic properties of these compounds as well as their 
performance in animal models of solid cancers remain unknown. 
A 2009 publication by Kazi et al. describes a discovery of a non-peptide proteasome inhibitor 
[198]. In an effort to discover novel proteasome inhibitors, Kazi et al. screened 3,229 small 
molecules comprising three small compound libraries curated by the NCI for their ability to 
inhibit purified 20S proteasome CT-L activity. Among eight hits, compound PI-083 (NSC-
45382) was the most potent with an IC50 of 1 µM (Figure 1.9). PI-083 also inhibited 
proliferation and induced apoptosis in several solid cancer cell lines in. IC50 values for a 72-
hour MTT assay ranged from 1.7 to 11 µM across 10 solid cancer cell lines. In a mouse 
xenograft model using MCF-7 and A549 solid cancer cell lines, twice-weekly dosing of 1 
mg/kg PI-083 produced significantly lower tumor volumes than 1 mg/kg of bortezomib. 
Testing was not performed to determine whether PI-083 forms a covalent bond with the 
proteasome or whether its inhibition is reversible. The authors did, however, generate a 
plausible model of the PI-083:proteasome complex via molecular docking. They note that 
their study could not rule out a covalent mechanism of action for PI-083 where the 
naphthoquinone chloro substituent could potentially be displaced via an attack by the 
catalytic Thr1 residue’s hydroxyl group leading to the formation of a covalent complex. 
A subsequent 2010 publication examined the structure-activity relationship for PI-083 and 
its analogues and provided further insight into its mechanism of action [199]. A dialysis 
experiment was performed to examine the reversibility of PI-083 binding to purified 20S 
proteasomes. Immediately after the start of dialysis, an initial test showed that proteasome 
CT-L activity was at approximately 12% of control. Proteasome activity rose gradually as 
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dialysis continued reaching approximately 24% of control at 2 hours and approximately 35% 
of control after 18 hours. In contrast bortezomib-treated proteasomes showed <5% activity 
at the start of dialysis reaching approximately 15% after 18 hours. Based on the slow return 
of proteasome activity in PI-083-treated proteasomes, the authors concluded that PI-083 is 
likely to act as a covalent reversible inhibitor. As in their previous publication, molecular 
modeling suggests that the naphthoquinone’s chloro substituent is poised to be displaced by 
the Thr1 nucleophile forming a carbon-oxygen covalent bond between PI-083 and the 
proteasome’s β5 catalytic subunit. This publication also demonstrated the design, synthesis, 
and testing of over 50 analogues of PI-083, based on traditional medicinal chemistry as well 
as molecular modeling. Unfortunately, none of the tested compounds provided an 
improvement in potency as compared to PI-083. In further support of the role of the 
naphthoquinone 2-chloro substituent, changes from chlorine to hydrogen or to a methyl 
group lead to a severe loss of activity. In general modifications of the sulfonamide’s N-pyridyl 
group to other heteroaromatics such as to 2-thiazole were the best tolerated with a 3.3-fold 
reduction of CT-L inhibitory potency in this case. The discovery of another novel structural 
class of proteasome inhibitors was reported by Gallastegui et al. in 2012, this time both 
reversible and non-covalent [200]. As in many previously reported efforts, a library of small 
molecule of compounds was screened in vitro for their ability to inhibit proteasomal 
fluorogenic peptide hydrolysis. This screen identified an N-hydroxyurea compound dubbed 
‘compound 1’ which was previously reported as an inhibitor of 5-lipoxygenase and is 
structurally similar to the FDA-approved 5-lipoxygenase inhibitor zileuton (Figure 1.9). 
Compound 1 was a relatively weak inhibitor of yeast proteasome CT-L activity (Ki = 23 µM) 
but appeared to have at least moderate specificity for yeast CT-L activity over yeast T-L or C-
L activities. Interestingly, compound 1 is structurally dissimilar from the majority of known 
proteasome inhibitors and an X-ray crystallographic structure of compound 1 bound to yeast 
20S proteasome revealed a unique binding mode. This structure revealed no interactions 
between the N-hydroxyurea moiety and the catalytic Thr1 residue indicating a non-covalent 
mechanism of action. The compound’s propynyl-benzene group was shown to extend into a 
novel sub-pocket of the S1 substrate binding pocket with the 3,3-methylbutoxy group 
interacting with a novel sub-pocket of the S3 binding pocket. In order to determine a 
structure-activity relationship for this scaffold and improve inhibitor potency, the authors 
synthesized 50 analogues of compound 1 with guidance from molecular docking studies. 
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Modifying the 3,3-methylbutoxy group to a 1-adamantyl ether as well as introducing a methyl 
group at the carbon adjacent to the hydroxylated nitrogen yielded a racemic mixture with an 
inhibitory potency over 200-fold greater than the initial hit, compound 1. Testing of the 
individual enantiomers yielded compounds 9 and 10 with S and R configurations at methyl 
substituted carbon (Figure 1.9). Compound 10, the R-isomer, was found to be an extremely 
potent inhibitor of yeast CT-L activity with a Ki value of 34 nM (IC50 = 340 nM). Unfortunately, 
this series of compounds has not been studied in further publications with regards to activity 
against cancer cell lines or animal models of cancer. Depending on the pharmacokinetic 
characteristics of compound 10, it could be a promising lead for further development.  
One final series of novel proteasome inhibitors of note are the oxadiazole-isopropylamide 
compounds discovered via additional efforts from the researchers based at the University of 
South Florida and Moffitt Cancer Center who previously reported the discovery of PI-083 and 
related compounds. The effort to discover and characterize this series of compounds was 
reported in two articles published in 2013 and 2014 [201, 202]. They began with a larger-
scale screen for compounds which inhibited the CT-L activity of purified 20S rabbit 
proteasomes, this time using a 50,000 compound library. Compound 1, dubbed PI-1833, was 
identified as a potent hit with an IC50 of 0.60 µM against proteasome CT-L activity (Figure 
1.9). Several series of analogues of PI-1833 were synthesized and tested for their ability to 
inhibit proteasome activity in vitro. Modification of the amide N-isopropyl group to several 
other alkyl groups resulted in loss of activity, with N-isobutyl and N-ethyl groups retaining 
the most potency. The next modifications were targeted at the two p-methylphenyl groups 
located at either ends of PI-1833. An extensive series of analogues was synthesized and 
tested, and in this case a number of modifications were well tolerated with some yielding 
improved potency relative to the lead compound. Exchanging the R2 p-methylphenyl group 
for a m-pyridine group yielded a 2.7-fold improvement in potency. Combining this 
modification with a p-(n-propyl)phenyl group in the R1 position yielded compound 43, later 
dubbed PI-1840 (Figure 1.9). This was the most potent compound of the series with an IC50 
of 0.027 µM. Modifications of the central portion of the molecule, such as an amide-to-urea 
change or an ether-to-amine change, were also tested but resulted in significant loss of 
activity. Notably PI-1840 had IC50’s of >100 µM for proteasomal C-L and T-L activities 
suggesting a strong binding preference for proteasomal CT-L subunits (β5 and/or β5i) over 
57 
 
other catalytic subunits. When tested for its ability to inhibit proteasomal CT-L activity in 
intact MDA-MB-468 cells, PI-1840 had a nearly 10-fold higher potency than PI-1833 (IC50 = 
0.37 vs. 3.5 µM), suggesting that PI-1840 retains acceptable cellular permeability. PI-1840 
likewise demonstrated an improved ability to inhibit MDA-MB-468 proliferation by 
approximately 10-fold as compared to PI-1833. 
Although PI-1840 was not further validated in the 2013 publication by Ozcan et al. [201], this 
series of compounds was further explored in a subsequent publication [202]. Interestingly, 
when PI-1840 was assayed for its ability to inhibit purified 20S human immunoproteasome 
CT-L activity, the IC50 was 2.17 µM, more than 100-fold less potent when as compared to its 
IC50 against 20S rabbit constitutive proteasome. This is significant in that it may demonstrate 
the potential for non-peptide non-covalent inhibitors to specifically target individual 
constitutive or immunoproteasome subunits. However, as PI-1840 was not tested against 
human constitutive proteasome, the possibility exists that some or all of this difference in 
potency could be related to the minor sequence differences between human and rabbit 
proteasomes. To conclusively determine whether PI-1840 acts as a covalent inhibitor, 
purified 20S rabbit proteasome was incubated with PI-1840 or with lactacystin as a positive 
control. Tryptic digests were analyzed via LC-MS/MS. In the lactacystin-treated sample, a 
clasto-lactacystin-modified TTTLAFK peptide was identified, originating from the N-
terminus of the β5 catalytic subunit. Modified β1 or β2 N-terminal peptides were not 
observed. In the case of the PI-1840-treated proteasomes, only unmodified β1, β2, and β5 
N-terminal sequences were observed indicating that PI-1840 inhibits the β5 catalytic subunit 
without covalently modifying it. A dialysis experiment was also performed to compare the 
reversibility of PI-1840 and the control compound lactacystin. Whereas lactacystin-treated 
proteasomes only recovered approximately 10% activity after 18 hours of dialysis, 
proteasomes treated with PI-1840 recovered approximately 25% activity in 4 hours with 
activity being fully restored after 18 hours. Next, their efforts turned to studying the effects 
of PI-1840 in cell line models. As in their previous publication, the ability of PI-1833 and 
PI-1840 to inhibit proteasome CT-L activity in intact MDA-MB-468 cells was tested. Again 
PI-1840 was shown to be approximately 10-fold more potent than PI-1833, but the absolute 
potencies were lower (IC50 = 1.55 vs. 11.6 µM) than those reported in the 2013 publication 
by Ozcan et al. A 120-hour MTT assay was used to measure PI-1840’s potency against several 
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solid cancer cell lines. IC50 values ranged from 2.2 µM against the breast cancer cell line MDA-
MB-231 to 45.2 µM in the renal cell carcinoma cell line RXF 397. PI-1840 was then compared 
to bortezomib in a nude mouse xenograft model of solid cancer using MDA-MB-231 cells. 
PI-1840 was dosed daily for 14 days at 150 mg/kg via intraperitoneal injection. Bortezomib 
was dosed at 1 mg/kg i.p. twice weekly for two weeks. During the 14-day treatment period, 
the tumor volume for bortezomib-treated animals was not significantly different than for the 
vehicle-treated control group. In contrast, animals treated with PI-1840 had significantly 
lower tumor volume than the control group (p < 0.05). It should be noted that the total dose 
for PI-1840 was over 500-fold greater than for bortezomib, and that that PI-1840-treated 
animals did still experience a net growth in tumor volume (+69%) during the 14-day 
treatment period. In conclusion, PI-1840 has been demonstrated to be a potent non-peptide 
non-covalent reversible inhibitor of proteasomal β5 activity. While low-micromolar doses of 
PI-1840 did inhibit cell viability in a 120-hour MTT assay, measurements of CT-L activity 
from intact cells treated with PI-1840 showed less inhibition than might be expected for a 
compound with nanomolar potency in vitro. Specifically, 59% inhibition was observed when 
MDA-MB-213 cells were treated with 20 µM PI-1840 for 2 hours. The observed inhibition was 
in the 85-90% range for several cell lines, but there was not a clear correlation between CT-L 
inhibition and MTT assay potency. There are several possible explanations for these 
discrepancies. One possibility is poor cellular permeability, or the metabolism of PI-1840 
within cancer cells. PI-1840’s high selectivity for the β5 subunit could also reduce its 
cytotoxic activity as selective β5 inhibitors have been demonstrated to be less cytotoxic than 
combined inhibitors of β5 and β5i [118]. Another potential factor is the reversible nature of 
PI-1840 which can effect assays of proteasome activity. When cells are treated with a 
reversible proteasome inhibitor, lysed, centrifuged, and then diluted in assay buffer, the drug 
concentration is likely to be reduced by dilution as compared to the original intracellular drug 
concentration. Considering that PI-1840 appears to be a slowly-reversible inhibitor in 
dialysis experiments, drug molecules may dissociate from the proteasome between the 
collection of intact cells and the final CT-L activity assay, effectively reducing the inhibitory 
effect of the PI-1840 in these types of assays relative to its activity in intact live cells. Lastly, 
it would be useful to perform animal pharmacokinetic and pharmacodynamics studies of 
PI-1840 to determine whether it remains effective at doses lower than 100 mg/kg daily and 
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to determine its rate of clearance, route of metabolism, and its ability to enter into xenograft 
tumors.   
In summary, while a number of non-covalent proteasome inhibitors have been identified, 
only a small number have been validated in animal models and shown to demonstrate 
anticancer activity in vivo. Though other research groups continue to make progress towards 
the development of efficacious non-peptide non-covalent inhibitors, we feel there is still 
significant room for further improvement and understanding in this area.  
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Figure 1.9 Chemical structures of non-peptide and non-covalent proteasome inhibitors 
 See accompanying text in section 1.8.1 for additional information on these non-peptide 
and/or non-covalent inhibitors of the proteasome.  
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1.9 Summary and Rationale for Further Research  
From early research in the late 1970’s to today, our collective knowledge of the ubiquitin-
proteasome system has grown in leaps and bounds enabling the development and FDA 
approval of three proteasome inhibitors for the treatment of multiple myeloma. Collectively, 
bortezomib, carfilzomib, and ixazomib have seen widespread clinical use, contributed to 
significant improvements in MM patient well-being, and have achieved combined annual 
sales in excess of $3.5 billion USD. According to a wide array of preclinical experiments, 
conventional proteasome inhibitors such as bortezomib and carfilzomib are active not only 
against MM cell lines but also exhibit potent cytotoxic and antiproliferative activity against a 
broad spectrum of cancer cell lines including colon, pancreatic, renal, and lung cancer cell 
lines. Bortezomib and carfilzomib also have proven activity in mouse xenograft models of a 
number of solid cancer types. Furthermore, the proteasome is believed to be essential for the 
survival of all cells and there exists a strong mechanistic rationale for the cytotoxic activity of 
proteasome inhibitors in solid cancer cells. Despite these promising preclinical results, a 
large number of clinical trials of bortezomib and carfilzomib in patients with various solid 
cancers have shown disappointing results.  
It is our belief that there exists an opportunity to develop novel proteasome inhibitors with 
improved clinical activity in a variety of solid tumor types. Although proteasome inhibitors 
have contributed to major improvements in the survival and well-being of multiple myeloma 
patients, myeloma represents only approximately 2% of annual US new cancer cases and 
approximately 2% of annual US cancer deaths. When taken together, solid cancers account 
for the vast majority of new cancer cases in the US and caused over 400,000 deaths in the US 
in 2016 [203]. Although the treatment landscape is unique for each type of cancer, there are 
a number of solid cancer types with high mortality rates and there exists a significant need 
for improved therapeutic options for these patients [204, 205]. This work was undertaken 
with the goal of identifying novel inhibitors which could serve as a starting point for a new 
generation of proteasome inhibitors with superior clinical activity against solid cancers as 
compared to existing FDA-approved proteasome inhibitors. 
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 HYPOTHESIS AND SPECIFIC AIMS 
The main goal of this research was to discover and develop novel non-peptide non-covalent 
proteasome inhibitors with improved activity against solid cancers as compared to 
conventional proteasome inhibitors such as bortezomib or carfilzomib. In clinical trials, 
bortezomib and carfilzomib have shown poor activity against solid cancers despite promising 
activity in preclinical studies.  
Although the reasons for this discrepancy between clinical trial experience and pre-clinical 
data are as yet unknown, it is our hypothesis that it results from sub-optimal pharmacokinetic 
and pharmacodynamic properties, examples of which include rapid metabolic inactivation of 
active drug, poor drug distribution into solid tumors, or off-target activities which limit the 
maximum tolerated dose. We also hypothesize that these sub-optimal properties may stem 
from the common structural heritage of conventional proteasome inhibitors: a peptide 
backbone combined with a reactive covalent warhead.  
By avoiding these structural features, we believe that there exists an opportunity to develop 
proteasome inhibitors with improved pharmacokinetic and pharmacodynamic properties 
which may exhibit improved activity in patients with solid tumors.  It is our hypothesis that 
compounds with non-peptidic structures, non-covalent and reversible modes of action, and 
unique selectivity profiles against the proteasome’s distinct catalytic subunits could have 
superior pharmacodynamic and pharmacokinetic properties and may bear improved activity 
against solid tumors relative to existing peptide-based covalent proteasome inhibitors. We 
also hypothesize that non-peptide inhibitors could offer additional benefits such as higher 
oral bioavailability and lower cost of manufacture.  
As described previously, there have already been a number of efforts to discover and develop 
non-peptide and/or non-covalent inhibitors of the proteasome. Unfortunately, all of these 
efforts suffer from one or more shortcomings. These include compounds with a peptide-
based structure or covalent mechanism of action, a lack of validation in cell culture or animal 
models of solid cancers, poor potency or activity in cell culture or animal models, or a lack of 
data on drug pharmacokinetics.  
63 
 
We have made efforts to avoid these issues in our own work, with the ultimate goal of 
delivering a compound or structural scaffold potentially suitable for clinical use in the 
treatment of solid cancers. Such a discovery could provide much needed therapies for the 
many forms of solid cancer in which treatment options are limited and life expectancies are 
short.  
Aim 1. Use a two-stage computational and in vitro screening method to identify structurally-
novel proteasome inhibitors from a large chemical library. High-throughput screening of 
small molecules against a receptor or enzyme target is a traditional method for drug 
discovery but this method can be prohibitively expensive due to the need for automated 
robotic systems and the use of large amounts of purified enzyme and the large number of test 
compounds which must be synthesized or purchased. In order to avoid these costs, we turned 
to an in silico screening approach to pre-select compounds with a high likelihood of binding 
the proteasome’s catalytic subunits, thus improving hit rate. We collaborated with Dr. Chang 
Guo-Zhan and postdoctoral researcher Dr. Vinod Kasam due to their expertise and experience 
in the area of structure-based virtual screening methods.  
Aim 2. Evaluate potential hit compounds and use traditional medicinal chemistry methods to 
generate an optimized lead compound based on its activity in vitro and in cell culture. 
Compounds identified via structure-based virtual screening were assayed in vitro for their 
ability to inhibit the activity of β5 and β5i catalytic subunits present in purified constitutive 
and immunoproteasomes. Compounds with positive inhibitory activity were profiled against 
other proteasome and immunoproteasome catalytic subunits and were tested for cytotoxic 
activity against human cancer cell lines in cell culture. Traditional medicinal chemistry was 
performed to design and synthesize analogues of the most promising hit compound. 
Compound analogues were assayed initially for in vitro for proteasome inhibitory activity and 
later for their cytotoxic activity in cell culture.  
Aim 3. Perform a detailed evaluation of the optimized lead compound using cell culture 
models of solid cancer cell lines, models of PI-resistant solid cancers, and mouse xenograft 
models of solid cancers. A lead compound was selected from among the synthesized 
analogues based on its in vitro and cellular potency and was evaluated for reversible 
proteasome inhibition using a jump dilution assay. Cell line models of bortezomib- and 
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carfilzomib-resistant solid cancers were used to quantify cross-resistance between 
traditional peptide-based covalent proteasome inhibitors and the lead compound. An in vitro 
assay of compound metabolism by pooled human hepatocytes was used to compare the 
potential metabolic stability of the lead compound with a conventional proteasome inhibitor. 
Lastly, to evaluate the lead compound’s activity in vivo, a mouse xenograft model of human 
prostate cancer was with bortezomib serving as positive control.  
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 MATERIALS AND METHODS 
Portions of the methods described below have been published previously [206, 207]. 
 
3.1 Structure-Based Virtual Screening 
A structure-based virtual screening (SBVS) method was used to identify potential 
proteasome-inhibiting small molecules from a large compound library. Compounds 
identified as being most likely to bind proteasome catalytic subunits were then tested for 
proteasome inhibitory activity in vitro. All computational modeling was performed by Dr. 
Vinod Kasam under the direction of Dr. Chang-Guo Zhan at the University of Kentucky.  
 
 Protein Preparation and Binding Site Definition 
A structure-based virtual screening (SBVS) method to identify potential proteasome-
inhibiting small molecules began with the preparation of a homology model of the human β5i 
catalytic subunit. As a crystal structure of human β5i was not available, the SWISS-MODEL 
workspace was used to generate a homology model from the human β5i sequence (FASTA 
P28062) and a BLAST search was used to identify a suitable template with an available X-ray 
crystallographic structure. In this case the human constitutive β5 subunit was chosen as the 
preferred basis for the homology model. The generated homology model was then quality 
checked using a Ramachandran plot assessment via PRO-CHECK. As the β5i ligand binding 
site is constructed both from β5i as well as the adjacent β6 protein, models of both proteins 
were used in subsequent steps. Due to the availability of pre-existing X-ray crystal structures, 
homology modeling was not required for the β6 non-catalytic subunit. 
In order to define the β5i-β6 binding site, a previously-published model of the peptide 
epoxyketone inhibitor UK-101 bound to β5-β6 was aligned to β5i-β6 and the UK-101 ligand 
was transferred to the β5i-β6 model. Next hydrogen atoms were added to the β5i-β6:UK-101 
model to assign protonation states and energy minimization was performed with a small 
number of steps to relax UK-101 and β5i-β6 side chains to more energetically-favorable 
positions. β5i-β6 histidine side chains were evaluated individually and assigned as being 
66 
 
protonated at the δ-position or at the ε-position. The β5i-β6 binding site was then defined as 
encompassing all β5i or β6 atoms within 10 Ǻ of the UK-101 ligand.  
 
 Homology Model Validation 
Further validation of the homology model was performed using a set of 16 peptide-based 
non-covalent inhibitors with known IC50’s against β5i as reported by Blackburn et al. in 2010 
[113]. These 16 compounds were first built in the SYBYL 6.9 molecular modeling package. 
Molecular docking of the β5i binding site and the 16 compound was performed using the 
GOLD suite with 50 poses generated per compound. GoldScore was then used to assess pose 
fitness and select an ideal protein-ligand binding pose which would serve as the initial 
structure for energy minimization followed by molecular dynamics (MD) simulation. 
Molecular dynamics simulations of the 16 peptide compounds with the β5i binding site were 
performed using the sander module of Amber9 with the Amber ff03 force field. Protein-ligand 
complexes were neutralized, solvated, energy minimized and heated prior to running MD 
simulations for 1 ns total time with a 2 fs time step. Once a stable MD trajectory was obtained, 
100 snapshots of the protein:ligand complex were obtained with 1 fs intervals between 
snapshots. Next, binding free energy calculations were performed using the molecular 
mechanics-Poisson-Boltzman surface area (MM-PBSA) method. Specifically, the binding free 
energy was calculated for each of the 100 snapshots and averaged to yield a calculated ΔGbind 
value. For each snapshot, the binding free energy was calculated as the difference between 
the protein-ligand complex free energy and the unbound protein free energy and the 
unbound ligand free energy. When comparing the calculated binding free energies of the 16 
peptide compounds with their experimentally-derived binding free energies, there was a 
positive linear correlation with R2 = 0.973.  
 
 Selection of the Best β5i Binding Site 
The molecular dynamics simulation of the binding between compound 16 and the β5i binding 
site was chosen as the starting point for further simulations due to compound 16’s superior 
binding affinity among the 16 tested non-covalent inhibitors. An additional 1 ns MD 
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simulation of compound 16 with the β5i binding site was performed under the conditions 
described above. Snapshots were taken every 10 ps and binding energy was calculated with 
the MM-PBSA method. Those snapshots with the best MM-PBSA energies were then 
visualized manually. As peptide based proteasome inhibitors are known to form β-sheet-like 
hydrogen bonds with β5i residues Ser21, Gly47, and Ala49 and β6 residue Asp125, 
interactions with these residues were considered to be of additional importance for the 
selection of potential inhibitory compounds [80, 208, 209]. After categorizing the best-
scoring snapshots based on these key residue interactions, the snapshots from 341 ps, 591 
ps, and 931 ps were considered candidates for final selection. The sixteen non-covalent 
peptide inhibitors were then docked with these three snapshots using the methods described 
above and the MD simulation snapshot taken at 341 ps was selected due to its ability to best 
reproduce the binding poses of these 16 compounds. 
 
 Conformations of Chemical Compounds 
The University of Cincinnati Genome Research Institute (UC-GRI) chemical compound library 
was chosen for this virtual screening due to its availability to University of Kentucky 
researchers in accordance with a collaborative research agreement and the large number of 
drug-like compounds available within the library. The UC-GRI compound library database 
contains the structural information for 345,447 compounds which are available upon request 
as DMSO solutions. The OMEGA tool (OpenEye Software) was used to systematically generate 
multiple conformations from each 2D structure and to discard high-energy conformations. 
The maximum number of conformations per compound was set at 250 and a root mean 
square deviation (RMSD) of 0.8 Å was used to discard duplicate conformers. A total of 
approximately 2.1 million confirmations were generated and stored in a single binary file. 
  
 Rigid Molecular Docking 
Initial rigid molecular docking was performed using FRED 2.2.5 (OpenEye Software) using 
the conformations generated by OMEGA as input. FRED utilizes an exhaustive search that 
scans rotations and translations of each ligand conformation within the negative image of the 
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active site at a given resolution, 0.5 Å in this case. A smooth Gaussian shape fitting function 
was used to optimize the contact between the ligand surface and protein surface, and any 
ligand poses which clashed with the protein were rejected. Both the ligand poses and the 
protein were held rigid during this process. Conformations which survived this initial shape 
fitting processes were then passed to scoring functions. A series of three optimization filters 
were employed consisting of hydroxyl group rotamer optimization, rigid body optimization, 
and torsion optimization. In order to identify the ideal scoring function or functions, a 
preliminary docking trial was conducted using the set of 16 non-covalent peptide inhibitors. 
Scoring functions were chosen based on their ability both to reproduce known binding modes 
and to match the rank order of experimentally-determined compound β5i IC50 values. 
Exhaustive docking using ChemGauss3, ChemScore optimization, pose selection via 
consensus scoring (ShapeGauss, ChemGauss3, PLP, ChemScore), and lastly compound 
selection via ChemGauss3 and Chemscore produced the best results with the test set of 16 
compounds and was accordingly chosen for high-throughput virtual screening. The overall 
database of approximately 2.1 million conformations was split into sub-groups of 15,000 
conformations each. FRED docking of sub-groups were performed in parallel and in-house 
using distributed computing. The results from all sub-groups were merged and the 250,000 
best binding poses from non-redundant compounds were selected. Compounds were 
selected solely based on ChemGauss3 and ChemScore docking score without other 
constraints.  
 
 Flexible Molecular Docking 
The 250,000 best binding poses obtained from rigid molecular docking were subjected to 
flexible docking using Amber9 software. Preprocessing was performed by Amber9’s 
Antechamer module prior to flexible docking. General Amber Force Fields (GAFF) parameters 
were used for ligands and Amber ff03 parameters were used for the β5i-β6 protein binding 
site for molecular mechanics and molecular dynamics simulations. The overall procedure for 
flexible docking began with energy minimization of the protein-ligand complex in which all 
atoms are allowed movement. Specifically, we employed the steepest decent and conjugate 
gradient methods for 100 and 2400 iterations, respectively, on all atoms of each β5i:ligand 
complex. This was followed by a 20 ps MD simulation where the ligand and protein side 
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chains within 12 Å of the ligand were allowed to move. The protein backbone was restrained 
using a harmonic potential of 50 kcal•mol-1• Å-2. A cutoff distance of 12 Å was used when 
calculating non-bonded interactions. A distance-dependent dielectric constant of ε(r)=4r was 
used to mimic the effect of solvent. Following the 20 ps simulation, the final MD snapshot was 
fully energy minimized prior to calculating the binding free energy (ΔGbind) via molecular 
mechanics-Poission-Boltzmann surface area (MM-PBSA) and molecular mechanics-
generalized Born surface area (MM-GBSA) methods as implemented within Amber9. A list of 
the top 10,000 compounds each from the MM-PBSA scoring function and the MM-GBSA 
scoring function were generated independently. After removing duplicates, the two lists were 
combined to yield a single list of 15,000 top compounds intended for further study.  
 
 Identification of Key Interactions and Manual Visualization 
Compounds were next filtered based on the presence of at least one hydrogen bonding 
interaction with β5i residues Ser21, Gly47, and Ala49 or β6 residue Asp125. This produced a 
set of approximately 3000 compounds which were evaluated by manual visualization in VIDA 
(OpenEye Software) using the binding mode of Blackburn et al. compound 16 as a template. 
Compounds with multiple hydrogen bonds to previously listed ‘key residues’ and high 
similarity the binding pose of Blackburn et al. compound 16 were given highest priority. A 
total of 288 compounds were then selected for in vitro measurement of proteasome β5 and 
β5i inhibitory activity.  
 
3.2 Screening and in Vitro Measurement of Inhibitory Activity 
The 288 selected compounds from structure-based virtual screening were provided as 10 
mM DMSO solutions in four 96-well polypropylene storage plates and were stored at -20° C 
when not in use. Due to limited quantities, compounds were used as is without further 
purification. In vitro measurements of β5 and β5i inhibitory activity were performed in 96-
well polystyrene plates (Greiner Bio-One) with a final volume of 100 µL per well. First each 
well was loaded with 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% 
w/v SDS). Next test compounds were added at a final concentration of 5 µM via 0.4 µL of 1.25 
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mM DMSO stock solution. In some wells epoxomicin at 1 µM was used as a positive control or 
0.4 µL DMSO as a negative control. Next 50 ng of purified human 20S constitutive proteasome 
or immunoproteasome (Boston Biochem) was added to each well for the measurement of β5 
or β5i activity, respectively. Plates were then allowed to incubate for 1 hour at room 
temperature in the absence of light to allow slow-binding or irreversible inhibitors to act. 40 
mM DMSO stock solution of Suc-LLVY-AMC fluorogenic proteasome substrate (Bachem) was 
diluted into 20S proteasome assay buffer to form a 1 mM solution of Suc-LLVY-AMC. In order 
to initiate the β5 or β5i activity assay, 10 µL of the Suc-LLVY-AMC solution was added per 
well via multichannel pipette to yield a final substrate concentration of 100 µM. Final DMSO 
concentration was 0.65% v/v in all wells. Na Ra Lee provided assistance in conducting this 
initial screening.  
Following the initial 288-compound screen which utilized Suc-LLVY-AMC as a substrate, 
subunit-specific fluorogenic substrates were used to monitor proteasome inhibition, 
excluding the case of the β2 and β2i subunits, for which no specific substrate exists. For 
measuring activity of the β1, β1i, β2/β2i, β5, and β5i subunits we used 100 µM Ac-nLPnLD-
AMC, 100 µM Ac-PAL-AMC, 200 µM Boc-LRR-AMC (R&D Systems), 20 µM Ac-WLA-AMC, and 
100 µM Ac-ANW-AMC, respectively. Note that 0.35% w/v SDS was excluded from the 
proteasome assay buffer when measuring β2 or β2i with Boc-LRR-AMC due to its ability to 
precipitate this substrate. Ac-nLPnLD-AMC, Ac-PAL-AMC, Ac-WLA-AMC, and Ac-ANW-AMC 
were synthesized in house.  
The inhibition of proteasome activity was monitored by the fluorescence of free 7-amino-4-
methylcoumarin (AMC) which is released following the proteasomal hydrolysis of 
Suc-LLVY-AMC by the β5 or β5i subunit. This was done using a SpectraMax M5 plate reader 
(Molecular Devices). Each well in a 96-well plate was checked for fluorescence once per 
minute for a 90-minute period. The excitation wavelength was 360 nm and the emission 
wavelength was 460 nm. A cutoff filter was employed at 420 nm to improve signal to noise 
ratio. For each well, proteasome activity was calculated by taking the slope of a linear 
regression of the fluorescent signal (RFU) versus time (min) data set using GraphPad Prism. 
Percent activity remaining for any given compound was determining by dividing the slope 
(RFU/min) in the presence of the compound by the slope in the absence of inhibitor (DMSO 
control). Positive control wells containing 1 µM epoxomicin were used for normalization. 
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Proteasome inhibition assays were also performed using cell lysates a source of proteasomes. 
RPMI-8226 cells were permeabilized using a buffer containing 0.025% digitonin as well as 
50 mM Tris-HCl, 250 mM sucrose, 5 mM MgCl2, 1 mM dithreitol, 0.5 mM EDTA, and 2 mM 
ATP at pH 7.5 [210]. Cells were then centrifuged at 21,000g for 15 minutes in a refrigerated 
(4°C) rotor and the supernatant was collected and assayed for protein concentration using 
the Bradford assay (Bio-Rad). Single-use aliquots of supernatant were stored at -80°C prior 
to use. Each microtiter well contained 3 µg of total RPMI-8226 protein. Chymotrypsin-like 
(β5/β5i activity) was monitored using 100 µM Suc-LLVY-AMC as substrate. Caspase-like 
activity was monitored using 100 µM of Z-LLE-AMC (R&D Systems). Trypsin-like activity was 
monitored using 100 µM of Boc-LRR-AMC. Proteasome inhibition assays using cell lysate 
were otherwise performed as described in the previous paragraphs. Detergent (0.035% w/v 
SDS) was omitted when measuring trypsin-like activity due to its propensity to precipitate 
positively-charged peptide substrates.  
 
3.3 Cell Culture and Development of Drug Resistant Cell Lines 
Human cancer cell lines BxPC-3, H358, H23, LNCaP, Panc-1, and RPMI 8226 were obtained 
from the ATCC (American Type Culture Collection) and maintained in media as 
recommended by ATCC, either DMEM or RPMI 1640 (Gibco) supplemented with 10% fetal 
bovine serum (Atlanta Biologicals) and 1 mM sodium pyruvate (Sigma-Aldrich). All media 
contained 1.5 g/L sodium bicarbonate. Cells were maintained in a 37ºC water-jacketed 
incubator with 5% CO2 in air atmosphere. All cell lines were cultured every 3 days. For 
adherent cell lines, rinsing with HBSS solution (Gibco) followed by treatment with 0.05% 
trypsin-EDTA solution (Gibco) was used to dissociate cells from cell culture vessels prior to 
splitting and re-plating on new vessels. For suspension cell lines, centrifugation was used to 
isolate cells from cell culture media prior to re-plating on new vessels. BxPC-3 cell lines with 
acquired resistance to bortezomib or carfilzomib were generated by culture in the continuous 
presence of the respective proteasome inhibitor with gradually increasing drug 
concentration over time. Over a period of approximately 6 months, these BxPC-3 sublines 
were adapted to grow in the presence of 60 nM bortezomib for BxPC-3 Btz-R and 200 nM 
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carfilzomib for BxPC-3 Cfz-R. Na Ra Lee and Dr. Kimberley Carmony provided assistance in 
the development of these cell lines.  
3.4 Assaying Compounds for Cytotoxic or Antiproliferative Effects 
The effects of test compounds on cell growth and survival were assayed using the MTS cell 
viability assays or ATP quantification-based assays in 96-well formats. Cells growing in log 
phase were collected via trypsinization for adherent cell lines or via centrifugation for RPMI 
8226 and were then plated on 96-well cell culture-treated plates (USA Scientific) at a density 
of 7,000-10,000 cells per well for adherent cell lines or at 10,000 cells per well (5 x 104 
cells/mL) for the RPMI 8226 cell line. Cells were plated in an initial volume of 100 µL of cell 
culture media and then incubated for 24 hours. Test compounds were then added via an 
aliquot of DMSO stock solution. The final concentration of DMSO was minimized as much as 
possible via the addition of compounds from high-concentration stocks. Untreated control 
wells were treated with DMSO alone to match the DMSO concentration of test wells. 96-well 
plates were then incubated for 72-hours prior to performing MTS or ATP quantification 
assays. For MTS assays, 20 µL of CellTiter 96® AQueous One reagent (Promega) containing 
MTS and PMS was added to each well as is indicated in the manufacturer’s protocol. The 96-
well plate was then incubated at 37°C for 1-2.5 hours (depending on the cell line in use) to 
allow MTS reduction to occur and the amount of reduction was quantified by reading 
absorbance at 490 nm using a SpectraMax M5 plate reader (Molecular Devices). Wells 
containing no cells were used to normalize the results. ATP-based cell viability assays were 
performed using the CellTiter Glo luminescent cell viability assay (Promega). As indicated in 
the manufacturer’s protocol, 100 uL of CellTiter Glo reagent was pipetted into each well and 
the plate was mixed for 2 minutes on an orbital shaker and then incubated at room 
temperature for 10 minutes. Luminescence was then recorded using a Vertias microplate 
luminometer (Turner BioSystems) using a 1 second integration time. DMSO-treated control 
wells and wells containing no cells were included for normalization. Dr. Lin Ao provided 
assistance in performing cell culture cytotoxicity assays. 
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3.5 Resynthesis of Compound G4 and Synthesis of G4 Analogues 
In order to confirm its identity and activity, hit compound G4 was re-synthesized in-house. 
For a detailed description of the synthesis of G4 and G4 analogues see Miller et al. 2015 [206]. 
The synthetic scheme for the amide-linked analogue compound G4-1 is shown in Figure 3.1. 
In brief, p-cresol (4-methylphenol) is treated with acetic anhydride to yield p-tolyl acetate. A 
Fries rearrangement catalyzed by AlCl3 yields 2’-hydroxyl-5’-methylacetophenone. The 
phenolic hydroxyl group is then esterified with benzoyl chloride. Following reflux with 
potassium carbonate, this intermediate ester undergoes a Baker–Venkataraman 
rearrangement to yield the 1,3-diketone compound 1. Treatment with hydrazine forms the 
3,5-disubstituted pyrazole compound 2. This 1H-pyrazole compound is then substituted at 
the 1-position nitrogen using benzyl 2-bromoacetate. The final aromatic ring is installed by 
reacting the free phenolic hydroxyl group with 3-trifluoromethylsulfonyl chloride. Next the 
benzyl protecting group is removed via hydrogenation catalyzed by palladium on carbon. 
Deprotection results in a free carboxylic acid which then undergoes amide bond formation 
with (R)-(+)-1-Boc-3-aminopyrrolidine catalyzed by TBTU. In the final step, trifluoroacetic 
acid is used to remove the Boc (t-butyloxycarbonyl) protecting group yielding compound 
G4-1 as a trifluoroacetate salt. In some cases, deprotection was performed instead with 
hydrogen chloride in dioxane to yield G4-1 as its hydrochloride salt.  
The synthetic scheme for producing the original amine-linked compound G4 from 
intermediate compound 3 is shown in Figure 3.2. In this case lithium aluminum hydride is 
used to reduce the carboxylic acid to a primary alcohol which is then reacted with tosyl 
chloride before installing the final aromatic ring. The pyrrolidine ring is installed using the 
same Boc-protected precursor as was used for the synthesis of G4-1 before a final 
deprotection reaction using trifluoroacetic acid.  
Analogues of G4 and G4-1 were synthesized using generally similar schemes, for example 
substituting modified or alternate chemical precursors in at various points such as by using 
alternative sulfonyl chlorides in the synthesis of compound 4 or using alternative amines in 
the synthesis of compound 6. For further details, see Miller et al. 2015 [206]. The synthesis of 
G4, G4-1, and their analogues were performed by Do Min Lee.  
 
74 
 
3.6 Jump Dilution Reversibility Assay 
Jump dilution assays were performed to determine whether proteasome inhibition by G4-1 
and other compounds was reversible in nature. Cell lysate containing 30 µg total protein 
diluted in a small volume of 20S proteasome assay buffer was treated with 10 µM G4-1 for 30 
minutes in a cuvette. Suc-LLVY-AMC fluorogenic proteasome substrate was then added at a 
concentration of 100 µM. Proteasome activity in the presence of G4-1 inhibitor was then 
measured via the fluorescence of cleaved AMC. Next a large volume of proteasome assay 
buffer containing 100 µM Suc-LLVY-AMC was added to the cuvette while continually 
monitoring the AMC fluorescence signal. The volume of buffer added was sufficient to reduce 
the concentration of G4-1 by 25-fold from 10 µM to 0.4 µM. The increase in the slope of the 
fluorescence signal following dilution, if present, indicates reversible proteasome inhibition 
and can be quantified to estimate the speed of inhibitor dissociation from proteasome 
binding sites.  
 
3.7 Statistical Analysis 
Errors bars represent the standard deviation of the mean unless noted otherwise. Statistical 
analyses and graphing were performed in GraphPad Prism 6.01. Prism’s four-variable (top, 
bottom, Hill slope, and IC50) non-linear fit was used to obtain IC50 values from dose-response 
curves. Methods used to evaluate statistical significance are specified for individual figures.  
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Figure 3.1 Synthetic scheme for G4-1 including intermediate compound 3 
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Figure 3.2 Synthetic scheme of G4 from compound 3 
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3.8 Microsomal Stability Assay 
Pooled human liver or mouse liver microsomes were used to assess the in vitro metabolic 
stability of G4-1 relative to peptide-based inhibitors bortezomib and carfilzomib. In brief, 
assays were performed in 100 µL total volume containing 1 µM test compound 0.5 mg/mL 
microsomal protein, 100 mM Tris-Cl pH 7.4, and an NADPH-generating system (0.2 u/mL 
isocitric acid dehydrogenase, 5 mM isocitric acid, 5 mM magnesium chloride, 1 mM NADP+). 
For negative controls, NADP+ or liver microsomes were withheld from the reaction mixture. 
Pooled human liver microsomes were obtained from BD Biosciences (UltraPool) whereas 
mouse liver microsomes were produced in-house from BALB/c mice. Reactions were 
preincubated for 5 minutes at 37°C before starting reactions by the addition of NADP+. After 
0, 5, 10, or 20 minutes of additional incubation time, reactions were stopped by the addition 
of 100 µL ice-cold acetonitrile containing 1 µM phenytoin internal standard. This mixture was 
held on ice for 30 minutes followed by centrifugation at 16,100g for 15 minutes. The 
acetonitrile supernatant was then collected and 5 µL aliquots were assayed for 
unmetabolized parent compound concentration using liquid chromatography−tandem mass 
spectrometry performed on an Agilent 1200 HPLC instrument and an Applied Biosystems 
Qtrap 3200 mass spectrometer equipped with an electrospray ion source. This work was 
performed by Dr. Yan-Yan Zhang and Dr. Hyun-Young of the University of Illinois-Chicago. 
 
3.9 Mouse Xenograft Studies  
In vivo experiments were performed using six-week-old male athymic BALB/c nude mice 
(Orient Bio Inc., SungNam, Republic of Korea). Animals were handled in accordance with the 
guidelines of the National Institute of Toxicological Research of the Korea Food and Drug 
Administration as well as the regulations for the care and use of laboratory animals of the 
animal ethics committee of the Konyang University. To generate solid tumor xenografts, a 
suspension of LNCaP human prostate cancer cells were subcutaneously implanted using a 
total of 2 x 106 cells in a 50 µL injection volume. Once xenograft tumors grew to a tumor 
volume of approximately 100 mm3, mice were separated into three groups (n=5 each) to be 
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administered G4-1 (5 mg/kg), carfilzomib (5 mg/kg), or vehicle only (citrate buffer 
containing hydroxypropyl-β-cyclodextrin and 8% v/v DMSO). Injections were given 
intraperitoneally twice per week for a total period of 4 weeks. Tumor volumes were 
measured using calipers and the formula (width)2 × length/2 and body weights were 
measured every 4 days during the experimental period. On day 30, mice were euthanized by 
cervical dislocation and tumors were isolated, weighed, and photographed. This work was 
performed by Dr. Keun-Sik Kim of Konyang University.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
 
 DISCOVERY AND OPTIMIZATION OF A NON-PEPTIDE PROTEASOME 
INHIBITOR 
Portions of the results described below have been published previously [206].  
4.1 Introduction 
The clinical and commercial successes of bortezomib (Velcade®), carfilzomib (Kyprolis®), and 
ixazomib (Ninlaro®) have validated the proteasome as a valuable target in the treatment of 
cancer. While highly impactful in the treatment of multiple myeloma, these drugs have shown 
poor efficacy in the treatment of a variety of solid tumors, an outcome that contrasts with the 
broad activity of proteasome inhibitors against solid cancers in various preclinical models. 
While it is not yet well understood why existing proteasome inhibitors are ineffective in the 
treatment of solid tumors, it is our hypothesis that this discrepancy arises from suboptimal 
pharmacokinetic and pharmacodynamic (PK/PD) properties shared by these FDA-approved 
proteasome inhibitors as well as their susceptibility to a number of drug resistance 
mechanisms. The relative balance of activity of existing proteasome inhibitors against the six 
different constitutive and immunoproteasome catalytic subunits could also play a role in 
their efficacy. Of note, the vast majority of existing proteasome inhibitors are structurally and 
functionally alike, making use of a di-to-tetra-peptide backbone combined with a C-terminal 
reactive warhead which targets the proteasome’s Thr1 catalytic site. One promising approach 
for the development of proteasome inhibitors with improved PK/PD properties and reduced 
susceptibility to known drug resistance mechanisms is to identify structurally and 
functionally unique drugs. To pursue this goal, we chose to utilize a two-stage strategy where 
potential proteasome inhibitors would be identified by structure-based virtual screening and 
then later confirmed via in vitro inhibition assays utilizing 20S purified proteasomes and 
fluorogenic peptide substrates of proteasome catalytic subunits. While reports of high-
throughput screens to identify proteasome inhibitors can be found in literature, our two-
stage approach offered the potential to identify novel proteasome inhibitors without 
requiring expensive and resource-intensive high-throughput screening. 
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4.2 Structure-Based Virtual Screening 
Using the methods described in section 3.1, our collaborators in the laboratory of Dr. Chang-
Guo Zhan performed structure-based virtual screening (SBVS) on a library of approximately 
345,000 small molecules using a homology model of the immunoproteasome β5i binding site 
as a target. The β5i binding site was chosen in order to yield hits which were either non-
specific inhibitors of the β5 and β5i subunits or which were specific inhibitors of the β5i 
subunit. While non-specific β5/β5i inhibitors are generally most active against cancer cells 
and were the target of this study, β5i-specific inhibitors may have other therapeutic 
applications such as in the treatment of inflammatory disease. As shown by tests performed 
in our lab (unpublished) and in the literature, β5-specific inhibitors such as CPSI generally 
have minimal cytotoxicity and accordingly were not sought in the design of our screening 
approach [118]. Any β5i-specific compounds discovered could be pursued for alternative 
non-oncology applications in a separate study. As described in section 3.1.7, 288 compounds 
were ultimately selected as having the greatest likelihood of being bona fide β5i inhibitors 
based on structure-based virtual screening. These selected compounds were delivered from 
the University of Cincinnati dissolved in DMSO at a concentration of 10 mM on four 96-well 
compound storage microplates.  
 
4.3 Initial in Vitro Screening 
All 288 compounds were then tested for their ability to inhibit proteasome activity in vitro 
using both constitutive and immunoproteasomes. Suc-LLVY-AMC was chosen as a 
fluorogenic substrate and was used for measuring inhibition of β5 and β5i activity as it acts 
as a substrate of both subunits with roughly equal activity [211]. All 288 compounds were 
initially tested in a single-replicate format using a compound concentration of 5 µM. This 
initial test revealed 18 compounds which reduced β5 or β5i activity by 30% or greater. These 
18 active compounds were then re-tested for their ability to inhibit β5 or β5i activity in 
triplicate. For simplicity, compounds were named based on the 96-well plate they were 
stored in (plate A, B, C, or D) and the row and column designation on that storage plate. 
Compound G4 from plate D was identified as the most potent compound among those which 
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inhibited both β5 and β5i activities similarly. The structures of selected hit compounds are 
shown in Figure 4.1. The results of triplicate β5 and β5i inhibition testing are shown in Figure 
4.2. Among the 18 compounds which showed inhibition exceeding our threshold of 30% at 5 
µM, compound G4 from plate D (referred to simply as G4) demonstrated greater inhibition of 
the β5 constitutive proteasome subunit than other hit compounds and inhibited both β5 and 
β5i to a similar degree.  Many of the other active compounds displayed a significant 
preference for β5i over β5, perhaps due to the choice of β5i as the target for our initial virtual 
screening. Based on its potency and balanced β5/β5i inhibition profile, compound G4 was 
chosen for more in-depth testing.  
 
4.4 Hit Confirmation of G4 and Discovery of Compound G4-1 
In order to confirm the hit, we sought a secondary source of compound G4. As it was not 
available commercially, our in-house chemists attempted to synthesize it. In the course of an 
initial unsuccessful synthesis, compound G4-1 was synthesized as a potential precursor to 
G4. This compound differs from G4 by having an amide functional group in place of the amine 
which connects the pyrrolidine ring to the pyrazole core. Although G4 was ultimately 
synthesized by an alternate route given in methods section 3.5, compound G4-1 as well as 
other synthetic intermediates were tested to determine their proteasome inhibitory potency 
relative to compound G4. In order to generate a dose-response curve and more accurately 
compare the inhibitory potency of G4 and G4-1, we tested both compound against the β5 and 
β5i subunits at a variety of inhibitor concentrations. The percent of β5 and β5i activity 
remaining following treatment of 20S constitutive or immunoproteasomes with varying 
concentrations of G4 and G4-1 are shown in Figure 4.4. Based on this data, compound G4 was 
found to be approximately two-fold more potent against the β5 subunit than against β5i, with 
IC50 values of 2.8 and 6.3 µM, respectively. Interestingly, the amide-linked G4-1 demonstrated 
greater potency against both subunits, while retaining mild selectivity for β5 over β5i with 
IC50 values of 1.6 and 2.4 µM, respectively. Next we attempted to determine whether G4-1 
also acts similarly to G4 in living cells. Due to the difficulty of measuring proteasome 
inhibition in living cells, especially with regard to reversible non-covalent inhibitors, we 
compared their effects on cell viability. 72-hour cell viability assays were performed using 
three different NSCLC cell lines with G4 and G4-1. Against the H23, H358, and H460 cell lines, 
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G4 had an average IC50 of 7.4 µM and only minimal differences in potency across the three 
cell lines. G4-1 was slightly more potent with an average IC50 of 6.6 µM. As such we confirmed 
that G4-1 was more potent than the parent compound G4 in both proteasome inhibition 
assays and in vitro cytotoxicity assays. We also found that the concentrations at which G4 and 
G4-1 induced cell death were similar to the concentrations required to inhibit the majority of 
both β5 and β5i activity in vitro. Based on its similar or improved potency, shorter synthetic 
route, and easier generation of pyrrolidine ring analogues via peptide coupling reactions, we 
chose to use G4-1 as the lead compound for further studies of this class of compounds.  
 
4.5 Literature and Patent Background Research  
In order to determine whether G4 or closely related compounds had been previously 
investigated for use as proteasome inhibitors or had been investigated for other purposes, 
we performed a search of the chemical literature. SciFinder Scholar (Chemical Abstracts 
Service) was used to search for reported or patented chemicals bearing structural similarity 
to compound G4. Although this search revealed a total of 46 compounds with a structural 
similarity score (Tanimoto metric) above the threshold of 60/100, we found no evidence that 
any of these compounds had been previously reported as inhibitors of the proteasome. The 
most similar compound identified was CAS 175678-14-5, with a similarity score of 70/100. 
This compound was reported as an inhibitor of cyclooxygenase II, compounds which have 
been used medically for their anti-inflammatory and analgesic properties. The second most 
similar compound was CAS 1240781-81-0, with a similarity score of 69/100. This compound 
was reported as having a greater ability to inhibit the growth of cells which lacked the 
Neurofibromin 1 (NF1) gene as compared to cells which possessed NF1 in a phenotypic 
screen. The precise mechanism of action was not identified but EGFR (epidermal growth 
factor receptor) and Ras were suggested as possible candidate targets of this compound. 
Although these two compounds were identified has having the highest structural similarity 
to compound G4, their similarity scores are relatively low and close to the minimum 
threshold in both cases.  Likewise, by-hand comparisons reveal significant differences 
between the structures of these reported compounds and G4 itself. As such we cannot assume 
that G4 or analogues of G4 will share the same biological activities as CAS 175678-14-5 and 
CAS 1240781-81-0. The structures of these compounds are given in Figure 4.3. A patent for 
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compound G4 and a series of its analogues was filed following our discovery of their 
properties as proteasome inhibitors. This patent was granted in 2016 [212].  
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Figure 4.1 Chemical structures of selected hits from in vitro screening 
 
Figure 4.2 Proteasome activity remaining with 5 µM of selected hit compounds 
Fluorogenic substrates were used to measure catalytic activity of 20S purified human 
proteasomes following inhibition. Error bars represent standard deviation (n=3). 
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Figure 4.3 Chemical structures G4 and two structurally-similar compounds 
 
Figure 4.4 Dose-response curves for G4 and G4-1 against β5 and β5i subunits 
Error bars represent standard deviation (n=3) when large enough to be visible.   
 
E 
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Figure 4.5 72-Hour cytotoxicity of G4 and G4-1 against three NSCLC cell lines 
Error bars represent standard deviation (n=4) where large enough to be visble. 
E 
 
87 
 
 
 
4.6 Medicinal Chemistry Efforts to Optimize G4-1 
The next step in our research effort was to generate a basic structure-activity relationship 
(SAR) for G4-1 and related pyrazole-based compounds and, if possible, identify any analogues 
with greater potency as measured by proteasome activity and cytotoxicity assays. As 
mentioned in chapter 1, non-peptide and non-covalent inhibitors of the proteasome are at an 
inherent disadvantage when it comes to inhibitory potency. The greater the potency of our 
compound against the proteasome, the less the chance of off-target activity which could 
reduce the usefulness of these compounds as therapeutics. Figure 4.6 shows three locations, 
dubbed R1, R2, and R3, which were chosen as ideal candidates for the creation of analogues of 
G4-1. These three locations were chosen based on relative ease of synthesis and their likely 
contribution towards G4-1’s overall affinity for β5 and β5i binding sites.   
We first synthesized a series of 17 analogues of G4-1 modified at the R2 position. In most 
cases, the synthesis of these R2-modified analogues began from the carboxylic acid 
intermediate compound 5 shown in Figure 3.1 and a primary or secondary amine or alcohol 
was used to generate a resulting amine or ester product using the coupling agent TBTU in the 
presence of organic base. Compounds 2-7 and 2-16 were generated from G4-1 also using 
TBTU and organic base in conjunction with the correct carboxylic acid to generate a second 
amide bond at the pyrrolidine ring nitrogen. The structures of the resulting compounds are 
given in Figure 4.7. These 16 analogues were then screened for their ability to inhibit 
proteasome β5 catalytic activity in vitro at an initial concentration of 10 µM. As shown in 
Figure 4.8, while none of the tested analogues surpassed G4-1 in inhibitory potency, there 
was a wide range of potencies among the compounds allowing us to draw some conclusions 
about the SAR for this series of compounds. The data for compound 2-14 demonstrates that 
there is essentially no detectable loss of potency when switching from the (R)-isomer to the 
(S)-isomer. Looking at compounds 2-13 and 2-15, we see that switching to an ester linkage 
or N-methylating the secondary amine were well tolerated and resulted in only small losses 
in activity. Acylating the secondary amine, effectively altering its protonation state at 
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physiological pH, was moderately tolerated in compounds 2-12 and 2-16. Compounds 2-5 
and 2-8 are also notable due to their ability to retain much of G4-1’s inhibitory activity while 
replacing the pyrrolidine moiety with other groups. In both cases a nitrogen atom is still 
present and is separated from the amide nitrogen atom by a two or three carbon linker. 
Replacing the pyrrolidine ring with small heteroaromatic rings as in compounds 2-9 and 
2-10, or with a small aliphatic group as in compound 2-2 were resulted in a near-complete 
loss of activity. Notably, treating 20S proteasomes with compounds 2-2, 2-10, and 2-17 all 
resulted in a consistent increase in proteasome substrate hydrolysis as compared to control 
rather than inhibition. This effect was most pronounced for compound 2-17 which increased 
proteasome activity to 216% (± 8.38% SD) of the control at a concentration of 10 µM (Not 
shown on graph). This activating effect was found to exhibit a dose-response curve with 
proteasome activity increased to 302% of control at the highest tested concentration of 100 
µM. Structurally and chemically compounds 2-2, 2-10, and 2-17 have a number of differences 
but they are all bear relatively hydrophobic substituents when compared to G4-1 and 
relatively active analogs such as compound 2-5. Although this activating effect is notable, it 
may be an artifact of in vitro proteasome activity assays which rely on 20S proteasomes 
whose gates are opened by a low concentration of detergent rather than by regulatory 
particles or proteasome activators as occurs in vivo. Ultimately we were left with the 
conclusion that G4-1 is the most potent proteasome inhibitor among the 18 tested 
compounds. While there most likely exists an R2 analogue with greater potency, we decided 
to direct our efforts to the R3 position next rather than to further refine our R2 SAR.  
Due to the fact that the synthesis of R3-modified analogues was begun prior to our discovery 
that G4-1 was more potent that G4 both in vitro and in cellulo, these analogues were designed 
using G4’s amine linkage at the R2 position rather than G4-1’s amide linkage. Accordingly, we 
will use G4 as the point of comparison when evaluating these analogues. The synthesis of 
these compounds began with the 1,3-diketone precursor compound 1. This precursor was 
treated with 2-hydroxyethylhydrazine in ethanol under reflux to form two pyrazole 
compounds bearing an N-hydroxyethyl substituent at the N1 or N2 position. The desired 
N1-modified pyrazole was isolated and tosylated to activate the primary alcohol. This was 
followed by reaction with (R)-(+)-1-Boc-3-aminopyrrolidine and subsequent protection of 
the newly-formed secondary amine with a second Boc protecting group. This precursor 
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compound was then reacted with aromatic sulfonyl chlorides and acyl chlorides followed by 
dual Boc deprotection to give 8 R3-modiifed analogues of G4. The structures of these 
compounds are shown in Figure 4.9. These compounds were subsequently tested for their 
ability to inhibit 20S proteasome β5 activity at a concentration of 10 µM as shown in 
Figure 4.10. By examining this data, we can again draw some conclusions about the 
relationship between R3-group structure and β5 inhibitory activity. As was observed at the 
R2 position, all analogues tested were weaker inhibitors of β5 than the parent compound 
itself, G4. Compound 3-1 which exchanged the sulfonate ester for its carboxylic acid isostere 
resulted in the smallest reduction in potency. Compound 3-4 and 3-6 which modified the 
aromatic ring but maintained a substituent in the 3-position retained a moderate amount of 
activity. Other modifications such as the removal of the aromatic ring entirely (compound 
3-3), the use of benzyl ether linker (compound 3-2), or the introduction of additional ring 
substituents resulted in the largest loss of inhibitory activity. Notably all tested compounds 
still retained measurable activity at the test concentration of 10 µM. This is in contrast to the 
R2 position where some substituents resulted in a near complete loss of activity, or acted as 
activators of proteasome activity in vitro. Although alkyl sulfonates such as methyl 
methanesulfonate are known to act as reactive electrophiles, the finding that compound 3-1 
retained strong activity against β5 suggests that sulfonate reactivity is not involved in the 
mechanism of action of this class of compounds [213]. Furthermore, aryl arenesulfonates are 
not well known as reactive electrophiles. Based on our overall findings, we came to the 
conclusion that original 3-trifluoromethylphenylsulfonate ester group found in G4 and G4-1 
afforded the most potent β5 inhibitors and was the best choice among the tested options.  
Our final attempt to optimize this class of compounds was conducted at the R1 position (as 
shown in Figure 4.6). The synthesis of these R1-modified analogues was carried out using 
2-acetyl-4-methylphenol as a starting material. Analogous to the synthetic route shown in 
Figure 3.1, an aromatic, cyclic, or heterocyclic acyl chloride containing the desired R1 
substituent was reacted with this starting material to generate a 1,3-diketone intermediate. 
These compounds were then carried through the synthetic steps as shown in Figure 3.1 to 
form the pyrazole ring and install the R2 and R3 substituents to yield the final product. The 
structures of these R1-modified analogues are given in Figure 4.11. Due to the presence of a 
basic nitrogen, compound 1-7 required additional Boc protection and deprotection of this 
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nitrogen during synthesis to avoid unwanted side reactions. Compounds 1-8 and 1-9 were 
synthesized from the Boc-protected precursor to compound 1-7. In order to investigate the 
effects of these structural changes, we assayed these nine compounds against 20S 
proteasome β5 activity in vitro at a compound concentration of 10 µM. The relative amount 
of β5 remaining following treatment with compound 1-1 through 1-9 is shown in Figure 4.12. 
In contrast to our previous efforts at modifying positions R2 and R3, R1-modified analogues of 
G4-1 were found to have moderately increased potency in this assay. Using t-tests with Holm-
Sidak correction for multiple comparisons, we determined that compounds 1-3 (p<0.0005), 
1-6 (p<0.005), 1-7 (p<0.0001), 1-8 (p<0.0001), and 1-9 (p<0.0001) all inhibited β5 activity 
to a significantly greater degree than an equal concentration of G4-1. Although it is difficult 
to make SAR conclusions from a limited set of compounds, it appears that this class of 
compounds tolerates a variety of aromatic and non-aromatic groups at the R1 position 
without major effects on potency. Likewise, the inclusion of basic nitrogen atoms in 
compounds 1-7, 1-8, and 1-9, which would be expected to exist primarily as charged amines 
under assay conditions, did not harm inhibitor potency. 
In order to more accurately determine the inhibitory potency of compounds 1-3 and 1-7, a 
dose-response curve was obtained by measuring the degree of inhibition of β5 activity at 
compound concentrations ranging from 0.1 µM to 30 µM. While both compounds were found 
to be more potent than G4-1, the magnitude of change was relatively small. Compound 1-7 
was the more potent of the two analogues, with an IC50 that was reduced by 1.5-fold as 
compared to G4-1 (Data not shown). While any improvement in potency is potentially useful, 
the addition of a second basic nitrogen atom complicates the synthesis of this compound. As 
such we chose to use the original phenyl substituent at R1 in further investigations of this 
series of pyrazole-based inhibitors. Combined with the knowledge gained by studying 
analogues modified at the R2 and R3 positions, we chose to move forward with G4-1 as our 
lead compound.  
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4.7 Discussion 
While we were not able to make a direct comparison between the hit rate of our combined in 
silico and in vitro screening approach and more conventional high-throughput screening, the 
identification of 18 active compounds from a pool of just 288 assayed compounds is quite 
remarkable in comparison to many unbiased or naïve screens. Although compound G4 
demonstrated the most favorable inhibition profile for the goals of this project, other active 
compounds which were identified such as compound D2 from plate C and compound G6 from 
plate B have been studied for other purposes resulting in one additional publication to date 
[214]. After verifying that compound G4 inhibited both β5 and β5i activities in vitro with a 
reasonable dose-response curve, we attempted to synthesize the compound in-house. This 
lead to the discovery of compound G4-1, which likewise inhibits β5 and β5i activities, albeit 
with slightly greater potency. We also found that both compounds have cytotoxic activity 
against three non-small cell lung cancer cell lines with G4-1 again being slightly more potent. 
Although their cytotoxic activity does not directly show that these compounds are cell 
permeable and able to persist in cells, it does suggest it. We next attempted to explore the 
SAR of this 1,3,5-trisubstituted pyrazole scaffold against the β5 subunit in search of analogues 
with increased potency. In totality, the design, synthesis, and testing of 34 pyrazole analogues 
indicated that G4-1 was already acceptably optimized at the R1, R2, and R3 positions. We were 
also able to make some initial conclusions about the structure-activity relationship for this 
series of compounds with respect to the proteasome’s β5 subunit. While we did identify some 
analogues with moderately improved potency, we did not identify any analogue with greatly 
improved inhibitory activity. While it is likely that additional medicinal chemistry efforts 
could build off of our initial work to yield more significant potency improvements, we decided 
to move forward with G4-1 in order to investigate its effects in living cells in more detail.  
 
 
 
 
92 
 
 
 
Figure 4.6 Locations targeted for the design and synthesis of G4-1 analogues 
 
 
Figure 4.7 Partial structures of R2-substituted analogues of G4-1  
Where R1 is a phenyl group and R3 is a 3-trifluoromethylbenzenesulfonate group as in 
compound G4-1 shown in Figure 3.1. 
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Figure 4.8 Inhibition of 20S β5 by R2-modified analogues of G4-1 at 10 µM. 
Error bars represent standard deviation (n=3-5).  
 
 
Figure 4.9 Partial structures of R3-substituted analogues of G4 
Where R1 is a phenyl group and R2 is an amine-linked pyrrolidine group as in compound 
G4, shown in Figure 3.2. 
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Figure 4.10 Inhibition of 20S β5 by R3-modified analogues of G4 at 10 µM 
Error bars represent standard deviation (n=3). 
 
 
 
Figure 4.11 Partial structures of R1-substituted analogues of G4 
Where R2 is an amide-linked pyrrolidine group and R3 is a 3-trifluoromethyl-
benzenesulfonate group as in compound G4-1, shown in Figure 3.2. 
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Figure 4.11 Inhibition of 20S β5 by R1-modified analogues of G4-1 at 10 µM 
A control reaction containing no inhibitor but an equivalent amount of DMSO solvent in 
addition to purified 20S proteasome and fluorogenic peptide substrate is shown for 
reference. Error bars represent standard deviation (n=3-6). 
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 CHARACTERIZATION OF THE PYRZOLE-BASED NON-PEPTIDE 
PROTEASOME INHIBITOR G4-1 
 
Portions of the results described below have been published previously [206]. 
 
5.1 Introduction 
Our medicinal chemistry efforts to optimize G4 concluded that compound G4-1 was the most 
suitable candidate for further investigation. In order to evaluate G4-1’s potential as an anti-
cancer therapeutic, we planned to gather more detailed information about its activities in 
vitro and in cell culture, and ideally to test the compound in live animals should no 
development road blocks arise. In our previous work we showed that G4-1 was an inhibitor 
of β5 and β5i sites in in vitro assays of purified 20S proteasomes, and that it exhibited 
cytotoxic activity in a limited set of cancer cell lines. In order to move forward we needed to 
examine G4-1’s activity against other proteasome catalytic subunits, to measure its ability to 
inhibit the proteasome in complex cell-derived mixtures, and to test the reversibility of its 
inhibitory effect. Following this we would test G4-1’s cytotoxicity against a wider range of 
cancer cell lines, including those bearing acquired resistance to conventional proteasome 
inhibitors. Lastly we sought a method to estimate G4-1’s metabolic stability before moving to 
animal models.  
 
5.2 In vitro Proteasome Activity Profiling 
We had previously established that G4-1 inhibited both the β5 and β5i catalytic subunits in 
vitro with a 1.5-fold greater potency against the constitutive β5 subunit. We next examined 
G4-1’s ability to inhibit other 20S proteasome catalytic subunits. This data is shown in Figure 
5.1. Both the constitutive 20S β1 subunit and the homologous immunoproteasome subunit 
β1i were inhibited relatively potently by G4-1 with IC50 values of 2.90 and 2.89 µM, 
respectively. This selectivity profile is in contrast to the FDA-approved peptide-based 
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inhibitors bortezomib and carfilzomib. In this case of carfilzomib, it demonstrates high 
selectivity for β5 and β5i over β1 and β1i, with selectivity ratios of >72-fold [215]. Bortezomib 
has been reported to have at least 9-fold selectivity for β5 over β1, but potently inhibits the 
immunoproteasome β1i subunit without any appreciable selectivity [215]. While the roles of 
different proteasome subunits in the cytotoxic activities of proteasome inhibitors is fully well 
understood, there is published evidence that an inhibitor which targets β1 and β1i can 
potentiate the cytotoxic effects of a β5/β5i-targeting inhibitor [216]. We have also observed 
similar effects in our own research with peptide epoxyketones which specifically inhibit β1i 
only with >10-fold specificity. The addition of a non-cytotoxic concentration of the β1i 
inhibitor was shown to significantly increase cell death in combination with bortezomib or 
carfilzomib in two human myeloma cell lines (unpublished data). It is plausible that G4-1’s 
ability to inhibit β1 and β1i in addition to the two chymotrypsin-like subunits could increase 
its effectiveness against cancer cells. We also examined G4-1’s activity against the 
immunoproteasome’s trypsin-like catalytic subunit β2i. In this case we observed only partial 
subunit inhibition at a concentration of 100 µM and little to no inhibition at lower 
concentrations. Due to the high degree of similarity in the binding pockets of β2i and the 
constitutive subunit β2, we expect that G4-1 is a poor inhibitor of both subunits.  
 
5.3 Confirmation of Activity in Cell Lysates 
While purified 20S constitutive and immunoproteasomes are convenient for examining the 
in vitro activity of proteasome inhibitors, proteasomes in living cells tend to be singly- or 
doubly-capped with regulatory complexes such as the 19S regulatory particle or PA28αβ 
[217]. An in vitro cell lysate assay was used to observe the effects of G4-1 on proteasomes 
from a heterogeneous cellular source. Cell lysates were obtained from RPMI-8226 cells which 
are known to express all six catalytic subunits (Western blot, unpublished data) and using a 
permeabilzation method believed to preserve proteasomes in their intact and capped states. 
The addition of Mg-ATP during permeabilzation also acts to stabilize proteasomes capped by 
the ATP-dependent 19S regulatory particle  proteasomes [218]. Assays were performed in 
the presence of 0.035% SDS to activate 20S proteasome particles present in the lysate. Figure 
5.2 shows dose-response curves for G4-1 against the CT-L, C-L, and T-L activities of 
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RPMI-8226 lysate. CT-L activity (β5 and β5i) was inhibited potently with a calculated IC50 
value of 3.60 µM. As was observed using purified 20S proteasomes, C-L activity (β1 and β1i) 
was inhibited less potently with an IC50 value of 8.13 µM. Even at the highest tested 
concentration of G4-1, substrate hydrolysis at approximately 15% of control was observed. 
Whether this is due to G4-1 not fully inhibiting the β1 and β1i subunits, or due to a 
non-proteasomal enzyme hydrolyzing the Z-LLE-AMC peptide is unknown. Trypsin-like 
activity was not inhibited by G4-1, with >90% activity remaining at all tested concentrations. 
Overall these results roughly mirror those observed using purified 20S proteasomes, with 
acceptable difference which may be explained by factors such as altered enzyme and 
substrate concentration. This data also confirms that G4-1’s inhibitory activity is not limited 
to assays which rely on purified 20S proteasomes.  
 
5.4 Jump Dilution Assay 
We next used a jump dilution assay to measure the ability of G4-1 to dissociate from its 
proteasome binding sites. In this assay, a concentrated solution of cell lysate is treated with 
an inhibitory concentration of G4-1 in a microcuvette. As described in the methods section, 
RPMI-8226 cell lysate was used as a concentrated source of proteasomes. In the case of 
covalent irreversible inhibitor such as the epoxyketone carfilzomib, reducing the free 
inhibitor concentration (via dilution or methods such as membrane dialysis) does not result 
in an increase in proteasome substrate hydrolysis. In contrast, substrate hydrolysis is 
expected to increase in the case of a reversible inhibitor as the shift in equilibrium favors the 
dissociation of the inhibitor from its binding sites. The rate at which this increase occurs may 
differ based on the residence time of the inhibitor [219]. Figure 5.3 shows the results upon 
diluting a solution of cell lysate pre-treated with 10 µM G4-1 by 25-fold with buffer giving a 
final inhibitor concentration of 0.25 µM. Suc-LLVY-AMC was present as substrate of β5 and 
β5i at a concentration of 100 µM. Data collection was begun within 15 seconds after dilution, 
with AMC fluorescence being measured every 10 seconds for a total of 30 minutes. A non-
linear regression was used to calculate the observed rate constant which represents the rate 
at which enzyme activity returns to steady-state following dilution. The rate constant, kobs, 
was found to be 0.00356 s-1 which translates to a half-life of 195 seconds. The R2 value for 
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this regression was greater than 0.999. Ultimately the key finding from this experiment is 
that dilution of a mixture containing compound G4-1 and proteasomes does result in a 
restoration of proteasome substrate hydrolysis. Additional data about the rate of G4-1’s 
association and dissociation from proteasome binding sites would be better obtained using 
more advanced techniques such surface plasmon resonance spectroscopy [220].  
 
5.5 Comparisons of Cytotoxicity Across Multiple Cancer Cell Lines 
Having previously established that G4-1 was cytotoxic against three NSCLC cell lines (H23, 
H358, and H460), we tested G4-1’s activity in a variety of other cell lines, including both solid 
cancer cell lines and multiple myeloma cell lines. As described in chapter 1, both bortezomib 
and carfilzomib are active in a wide variety of cancer cell lines with relatively few exceptions. 
The NCI’s 60 cell line panel (NCI-60) assays of bortezomib and carfilzomib highlight this. 
Averaging data from bortezomib’s multiple submissions to the NCI-60 screening program, 
the difference between the lowest GI50 for any one cell line and the highest GI50 for any cell 
line was only 20-fold (GI50 2.2 nM vs. 44 nM). This is in contrast to the higher values obtained 
for targeted therapies such as the kinase inhibitors erlotinib, imatinib, ibrutinib, and gefitinib 
which had ratios of 1880-fold, 1770-fold, 960-fold, and 250-fold, respectively. In order to 
examine G4-1’s cytotoxic potency in other cell lines, we performed 72-hour viability assays 
with the MM cell line RPMI-8826, the prostate cancer cell line LNCaP, and the pancreatic 
cancer cell lines Panc-1, BxPC-3, and AsPC-1. The results of these viability assays, along with 
previous data from NSCLC cell lines is shown in Figure 5.4. IC50 values as calculated using a 
four-parameter variable slope model are shown inset. Note that in the case of LNCaP, the 
dose-response curve appeared to demonstrate two slopes, a shallower slope at low doses and 
a steeper slope at higher doses. Accordingly, the R2 value for the regression was lower than 
typical at 0.974. Across the eight cell lines we tested, G4-1’s IC50 ranged from 6.5 to 16.9 µM. 
At G4-1 concentrations of 50 µM or higher, ≥95% loss of viability was observed in all cell lines. 
These results indicate that G4-1 retains its efficacy across this sampling of cancer cell lines. 
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5.6 Evaluating G4-1 in Proteasome Inhibitor-Resistance Cell Lines 
Considering the potential role of resistance mechanisms in the response to proteasome 
inhibitor therapy as discussed in chapter 1, we next sought to examine whether G4-1 could 
retain activity in cell line models of proteasome inhibitor resistance. In order to do so we 
utilized a pair of BxPC-3 pancreatic adenocarcinoma cell lines which had developed 
resistance to the conventional peptide-based proteasome inhibitors bortezomib and 
carfilzomib. These two cell lines were established by incubating parental BxPC-3 cells in a 
continuous sub-lethal concentration of drug, gradually increasing stepwise over a period of 
approximately 6 months. Thereafter, these cell lines were maintained in a stable level of 
proteasome inhibitor; 60 nM of bortezomib for the BxPC-3 Btz-R cell line and 200 nM of 
carfilzomib for the BxPC-3 Cfz-R cell line. In both cases the overall appearance and rate of 
growth of both cell lines appeared to be similar to that of the parental cell line. These cell lines 
were cultured in the absence of drug for one week prior to performing a viability assay to 
allow for a complete washout of bortezomib or carfilzomib. In order to confirm the degree of 
drug resistance exhibited these cell lines, we performed 72-hour cell viability assays with 
bortezomib or carfilzomib. Analysis of this data showed that BxPC-3 Btz-R was 5.1-fold (IC50 
53.6 vs. 10.6 nM) less sensitive to bortezomib than the parental cell line. The BxPC-3 Cfz-R 
was 4.5-fold (IC50 97.2 vs. 21.6 nM) less sensitive to carfilzomib than the parental cell line. We 
also identified that the BxPC-3 Cfz-R cell line exhibited significant cross-resistance to 
bortezomib with 4.6-fold (IC50 48.0 vs. 10.4 nM) decrease in drug sensitivity relative to 
BxPC-3 cells.  Next a 72-hour viability assay was performed using variable concentrations of 
G4-1, again following a one-week washout period. As shown in Figure 5.5, the G4-1 IC50 for 
bortezomib-resistant cells was slightly lower than for parental cells and the G4-1 IC50 
carfilzomib-resistant cells was slightly higher than for parental cells. A two-tailed unpaired 
t-test was used to compare the log(IC50) of the regression curve of the Cfz-R cells with that of 
parental BxPC-3. No statistically significant difference was found between them (p=0.288). 
These results indicate that the resistance mechanisms in play in these cell lines with acquired 
resistance to conventional proteasome inhibitors do not afford them protection from the 
cytotoxic effects of G4-1. Unfortunately, our group and collaborators have done a significant 
amount of work to characterize the resistance mechanisms of these cell lines, their degree of 
relevance to the clinical use of bortezomib and carfilzomib is still unclear.  
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5.7 In vitro Metabolic Stability of G4-1  
Due to the presence of peptidase and epoxide hydrolase enzymes throughout many of the 
body’s tissues, the peptide epoxyketone inhibitor carfilzomib is metabolized extremely 
rapidly as described in section 1.7.8. It is only via the covalent effect of its reactive warhead 
that carfilzomib achieves the duration of proteasome inhibition required to effectively cause 
cytotoxicity. Although short-duration exposure to proteasome inhibitors can be cytotoxic, the 
required doses are much higher [221]. Due to their reversible mode of inhibition, non-peptide 
non-covalent proteasome inhibitors must exhibit good metabolic stability to achieve an 
appropriate duration of effect. In order to estimate the metabolic stability of G4-1, our 
collaborators exposed pooled human or mouse liver microsomes to a dose of 1 µM G4-1 for 
5, 10, or 20 minutes before halting the reaction and analyzing the concentration of G4-1 
remaining via LC-MS/MS. The in vitro metabolic stability of bortezomib and carfilzomib were 
also tested under the same conditions. Assays were performed using two replicates per 
experimental condition. In tests using pooled mouse (BALB/c) liver microsomes, 
experiments were performed both with and without the addition of an NAPDH regenerating 
system to examine the contribution of non-NADPH-dependent degradation to the overall loss 
of parent compound. In tests using pooled human liver microsomes, G4-1 was tested with 
and without NADPH regenerating system whereas bortezomib and carfilzomib were tested 
only with NADPH regenerating system. The results of these experiments are shown in Figure 
5.6. In the presence of mouse liver microsomes, G4-1 was metabolized more slowly than 
epoxomicin or bortezomib. In the presence of NADPH, >95% of carfilzomib was metabolized 
within 5 minutes and >70% of bortezomib was metabolized after 20 minutes. In contrast, 
over 80% of G4-1 remained unchanged after 20 minutes of incubation. Although the apparent 
rate of metabolism of each drug was slower when using human liver microsomes, the overall 
trend was the same. In this case 95% of G4-1 remained unmetabolized at 20 minutes as 
compared to 74% of bortezomib and just 1% of carfilzomib. While in vitro assays using liver 
microsomes are not a substitute for the measurement of pharmacokinetic parameters in 
living animals, they are a useful tool for the early identification of drug candidates likely to 
suffer from rapid clearance [222]. Based on these preliminary results we found no reason to 
suspect that G4-1 is susceptible to rapid metabolism and we began planning to test the effects 
of G4-1 in vivo.  
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5.8 Mouse Xenograft Assay  
Considering our stated goal to develop novel proteasome inhibitors with improved efficacy 
against solid cancers, we designed a solid tumor xenograft experiment using BALB/c athymic 
nude mice. We utilized the LNCaP cell line, originally isolated from a patient with metastatic 
prostate adenocarcinoma. LNCaP cells were injected into nude mice and allowed to grow to 
a size of approximately 100 mm3 before beginning the drug treatment regimen. 
Tumor-bearing mice, organized into three groups of five subjects each, were treated with 
G4-1, carfilzomib, or vehicle alone twice per week for a period of four weeks. G4-1 and 
carfilzomib were both dosed at 5 mg/kg. Examples of carfilzomib mouse xenograft 
experiments in the scientific literature suggest that a twice-weekly dose of 5 mg/kg is 
sufficient to achieve a tumor growth reduction effect in many cases [133, 152, 223]. Lacking 
in vivo data on the pharmacodynamics of G4-1, we chose to match the carfilzomib dose by 
weight. During the treatment period, tumor volume and body weight were monitored prior 
to each dose. After the four-week treatment period, mice were sacrificed by cervical 
dislocation and tumors were excised and weighed. Tumor volume data is shown in Figure 5.7. 
Statistical analysis was performed first using two-way repeated measures ANOVA across the 
three treatment groups which indicated a highly significant (p<0.001) main effect of 
treatment. Post-hoc testing was performed pairwise on the treatment groups using Student-
Newmann-Keuls testing for each treatment day for a total of 27 comparisons. Annotations in 
Figure 5.7 indicate when tumor volume in G4-1- or carfilzomib-treated animals was 
significant reduced as compared to the control group. The difference in tumor volume 
between the G4-1 and carfilzomib treatment groups did not reach statistical significance 
except for day 27 (p<0.001).  
Figure 5.8 shows changes in the body weight of xenograft-bearing mice over the four-week 
treatment period. Following an initial two-way repeated measures ANOVA which 
demonstrated a significant effect of treatment, Bonferroni post-hoc testing was used to 
examine whether animal body weight in the carfilzomib-treated or the G4-1-treated group 
differed significantly from the vehicle-treated group. While G4-1 did not have a significant 
effect on body weight for any measurement day, the body weight of carfilzomib-treated mice 
was significantly lower (p<0.01) than vehicle-treated mice on the last four measurement 
days.  Body weight can be useful as a basic non-invasive measure of animal health. Despite 
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the equal or greater reductions in tumor volume effected by G4-1 as compared to carfilzomib, 
G4-1 did not cause the same reduction in body weight observed in carfilzomib treated 
animals. In an attempt to remove the influence of tumor weight from body weight 
measurements, an average tumor density of 0.96 g/mL was calculated based on the average 
size and mass of the excised tumors. Body weight was then corrected by subtracting the 
tumor volume times 0.96 g/mL for each measurement. After performing this correction, the 
final non-tumor body weight of G4-1 treated animals was significantly higher (p<0.005) than 
that of animals in the vehicle-control group (22.9 ± 0.69 vs. 20.7 ± 0.66 grams, mean ± SD).  
The weight of the excised tumors also provides additional confirmation that G4-1 had a 
statistically-significant impact on tumor growth as compared to vehicle-treated animals. 
Figure 5.9 shows the average weight of excised xenograft tumors following sacrifice on day 
30. Both G4-1-treated and carfilzomib-treated groups had significantly lower (p<0.001) 
tumor weights as compared to tumors from the vehicle control group.  
In conclusion, a 5 mg/kg twice-weekly dose of G4-1 caused a significant reduction in both 
tumor volume and final tumor weight in nude mice bearing LNCaP xenografts. G4-1 
treatment did not significantly reduce overall body weight as compared to control. A mass-
equivalent dose of carfilzomib also significantly reduced tumor volume and tumor weight, 
however the magnitude of these effects was smaller than observed with G4-1. Carfilzomib 
treatment also caused a significant reduction in overall body weight as compared to control 
during the final two weeks of drug treatment. These findings indicate that G4-1 is acts as an 
anticancer agent in mice without generating any signs of overt toxicity.  
 
5.9 Discussion 
The experiments described in this chapter revealed a number of promising features of G4-1 
as an early therapeutic candidate including activity against multiple distinct proteasome 
subunits, cytotoxicity across a range of different cancer cell lines, both of hematologic and 
nonhematologic origin, a reversible mode of action, and high in vitro metabolic stability. 
Ultimately in vitro and in cellulo methods are significantly limited in their ability to predict 
the success of new therapeutic agents as compared to animal models of disease. Having 
104 
 
demonstrated that G4-1 reduces xenograft tumor volumes at the relatively modest dose of 
5 mg/kg twice per week, we feel that this series of compounds warrants additional research 
in order to make progress towards the development of novel anticancer agents. Further 
investigations of G4-1 (or an improved analogue thereof) are needed to confirm our results 
and to more thoroughly evaluate the preclinical properties of G4-1 before considering any 
potential use in the treatment of human disease. Potential avenues of future research will be 
discussed in chapter 6.   
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Figure 5.1 Inhibition of specific 20S subunits by G4-1 
Inhibition of specific proteasome subunits by G4-1 measured using purified 20S 
constitutive or immunoproteasome and subunit-specific fluorogenic peptide substrates 
as required. Error bars represent standard deviation (n=3).  
 
 
 
 
 
Figure 5.2 Inhibition of cell lysate proteasome activities by G4-1 
Chymotrypsin-like, caspase-like, and trypsin-like activities were measured in 
RPMI-8226 lysate using appropriate fluorogenic substrates. Error bars show SD (n=3). 
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Figure 5.3 Jump dilution assay of G4-1 in RPMI-8226 cell lysate 
A.) Full 30-minute data set, 10 second data collection interval. B.) First 10 minutes of 
data overlaid with a non-linear regression calculated from the full data set shown in A. 
The data shown represents only a single experiment.  
 
 
 
 
 
 
 
Figure 5.4 Evaluation of G4-1 in multiple 72-hour cell viability assays 
Error bars represent standard deviation (n=3-4).  
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Figure 5.5 Evaluation of G4-1 in cell viability assay PI-resistant BxPC-3 cell lines 
Error bars represent standard deviation (n=4).  
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Figure 5.6 In vitro metabolic stability assay of G4-1, carfilzomib, and bortezomib 
Experiments were performed both with and without the addition of NADPH, with the 
exception of the tests of carfilzomib and bortezomib using human liver microsomes. 
Filled circles with a solid line indicates with NADPH, open triangles with a dashed line 
indicates without NAPDH. Only two replicates were performed, both data points are 
plotted individually. Connecting lines between their means are shown. 
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Figure 5.7 Effect of G4-1 versus carfilzomib on mouse xenograft tumor volume  
Effect of twice-weekly 5 mg/kg carfilzomib or G4-1 on the growth of LNCap xenograft 
tumors in nude mice. Following initial two-way ANOVA analysis, two-way repeated 
measures Student-Newmann-Keuls (SNK) post-hoc tests were used to assess differences 
in tumor volume between treatment groups. Annotations indicate statistically-
significant differences from the vehicle-treated group: #: p<0.05, ##: p<0.01, *: p<0.005, 
**: p<0.001. Data is shown as mean ± standard error. 
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Figure 5.8 Effect of G4-1 versus carfilzomib on mouse body weight 
Effect of twice-weekly 5 mg/kg carfilzomib or G4-1 on overall body weight of mice 
bearing LNCaP xenograft tumors. Following two-way ANOVA, Bonferroni post-hoc 
testing was used to examine differences in body weights between treatment groups on 
each day. Annotations indicate statistically-significant differences from the vehicle-
treated group: #: p<0.01. Data is shown as mean ± standard error.  
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Figure 5.9 Effect of G4-1 versus carfilzomib on final tumor weight 
Effect of twice-weekly 5 mg/kg carfilzomib or G4-1 on excised tumor weight after four 
weeks of treatment. Data was analyzed using one-way ANOVA followed by SNK post-hoc 
testing. Annotations indicate statistically-significant differences from the vehicle-treated 
group: *: p<0.001. Data is shown as mean ± standard error.  
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 SUMMARY AND FUTURE DIRECTIONS 
While it is our goal and our hope that the work described here could lead to an approved 
human therapeutic based on the recently-identified G4/G4-1 pyrazole scaffold, drug 
development is a costly and laborious process, with only a tiny fraction of drug candidates 
reaching the market [224-226]. In order to evaluate the prospects of G4-1 or a related 
compound, a number of additional studies should be performed to better characterize G4-1 
as an anticancer agent. One first step could be additional medicinal chemistry efforts which 
aim to identify related compounds with greater inhibitory potency. With sufficient resources, 
a number of tools are available to aid in the optimization of drug potency. For example, X-ray 
crystallography has been successfully used to identify the binding mode of bortezomib, 
carfilzomib, and other proteasome inhibitors as well as their specific molecular interactions 
with catalytic subunits [227]. Identifying G4-1’s precise orientation, location, and 
interactions when bound to proteasome catalytic subunits could significantly aid in the 
rational design G4-1 analogues with improved binding affinity and hence improved potency. 
NMR (nuclear magnetic resonance) spectroscopy is likewise useful in the determination of 
ligand binding sites and poses, but protein size is a major limitation in these types of 
techniques [228]. As such, applying NMR spectroscopy to proteasome-ligand interactions 
requires specialized techniques as well as costly high field NMR instruments [229, 230]. G4 
analogues with increased potency against the proteasome are likely to require lower drug 
exposure in vivo which often results in less undesirable off-target activity. Ultimately, due to 
the proteasome’s inherent affinity for peptides, achieving high-potency non-peptide-based 
inhibitors is likely to require a significant research effort. 
Returning to G4-1 itself, this compound in many ways still remains uncharacterized, for 
example we lack an understanding of its pharmacokinetics in animal models. Acquiring 
pharmacokinetic data in mice, dogs, primates, or other species is an important step towards 
identifying a new compound’s suitability for use in humans. We have also not yet investigated 
the oral bioavailability of G4-1 or any of its analogues. Even in the unique area of oncology, 
orally-administered drugs have significant advantages over parenterally-administered drugs 
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in terms of ease of administration and convenience for patients. It would also be prudent to 
examine the pharmacodynamics of G4-1 in live animals. Understanding the duration and 
degree of proteasome inhibition generated by agents such as bortezomib, carfilzomib, and 
ixazomib has aided in optimizing the dosing schedules of these drugs for maximum efficacy. 
Although measurements of proteasome activity in red blood cells, PBMCs, or even tumor cells 
from patients or animals are now frequently performed, these assays are often incompatible 
with reversible inhibitors (excepting the case of slowly-reversible compounds such as 
bortezomib) due to their ability to dissociate from their binding site after collecting and lysing 
cells [231, 232]. Move advanced techniques which do not rely on long-term occupancy of the 
catalytic subunit binding site are required to investigate the in vivo pharmacodynamics of 
reversible proteasome inhibitors. One such technique suitable for use in mice is to create a 
xenograft composed of human cancer cells which express a fluorescent or luminescent 
protein which acts as a biosensor for proteasome activity [233, 234]. Proteasome activity in 
these xenografted cells can then be measured using non-destructive bioimaging techniques. 
It should also be noted that G4-1 has only been tested in a single animal model to date. A 
better understanding of G4-1’s profile of anticancer activity could be obtained using 
additional mouse xenograft models generated with human cancer cell lines originating from 
other (non-prostate) cancers. It would also be useful to examine G4-1’s activity in other types 
of animal models which more closely recapitulate the biology of human solid tumors. These 
include patient-derived xenograft (PDX) models as well as genetically-engineered mouse 
models (GEMMs) of cancer in immunocompetent mice [235].  
Preclinical screening of off-target activities could also be performed to gauge G4-1’s 
selectivity for the proteasome over other targets, and to identify potential liabilities. Such 
screens could include a variety of non-proteasomal proteases as well as a panel of common 
drug targets which may include various GCPRs, ion channels, enzymes, and nuclear receptors 
[236]. Gene expression profiling in cells treated with G4-1 could also be used to compare its 
effects on cellular mRNA levels to those of validated proteasome inhibitors such as 
bortezomib making it possible to characterize their similarities and differences [237, 238]. 
Additionally a large database of gene expression signatures of various other drugs are 
available for comparison [239, 240]. Other preclinical data of interest could include the 
identification G4-1’s metabolites in various species, the enzymes involved in G4-1 
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metabolism, whether G4-1 or its metabolites significantly inhibit any CYP P450 enzymes, and 
in vitro measurements of drug permeability and susceptibility to transporter-mediated efflux 
[241-243]. Preclinical data can also identify unwanted sources of toxicity, such as via assays 
for genotoxic activity. Moving back into animal models, acute and chronic toxicology studies 
are a prerequisite which must be filled before any attempt to examine a new compound’s 
effects on humans. To date we know very little by G4-1’s toxiological profile. 
Ultimately I feel that the discovery and development of G4-1 reported in this dissertation is a 
significant advancement towards the potential application of non-peptide non-covalent 
proteasome inhibitors in human patients. While non-peptide non-covalent inhibitors suffer 
from some disadvantages, such as lower potency, we believe that they could offer major 
advantages over existing peptide-based covalent proteasome inhibitors. These potential 
advantages include improved pharmacokinetics, broader subunit inhibition profiles, reduced 
susceptibility to drug resistance mechanisms, and greater drug tissue penetration. It is our 
hypothesis that these properties, while potentially beneficial in the treatment of multiple 
myeloma, may prove to be critical factors in identifying proteasome inhibitors which are 
efficacious in patients with solid tumors. Considering the massive success of existing 
proteasome inhibitors in improving the treatment of multiple myeloma, we believe that any 
effort to expand the use of PIs to solid cancers is worth pursuing. This holds true especially 
for those solid cancers which are relatively lacking in safe and effective treatment options 
such as pancreatic cancer, ovarian cancer, and glioblastoma. While there is a tremendous 
amount of work still required to progress G4-1 towards any potential use in humans, we have 
successfully identified a non-peptide non-covalent compound which inhibits multiple 
proteasome catalytic subunits at low micromolar concentrations. G4-1 furthermore induces 
cell death in a variety of human cancer cell lines at concentration of 5-15 µM. In mice bearing 
human prostate cancer xenografts, G4-1 was found to significantly reduce tumor growth 
without producing overt signs of toxicity. Regardless of the future prospects of G4-1 or its 
analogues as therapeutic agents, it is our belief that the documentation and publication of our 
methodology can contribute to the future discovery and development of novel proteasome 
inhibitors. There is still much to be learned about the proteasome and the potential for 
proteasome inhibitors to treat human disease. Our ultimate goal is to improve the lives of 
those affected by cancer. Over the past decade and a half, bortezomib, carfilzomib, and 
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ixazomib have collectively made a tremendous positive impact on the lives of multiple 
myeloma patients. We can only hope that continuing research into the development of novel 
proteasome inhibitors will lead to an even greater impact for patients suffering from cancer 
of all types.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Zachary C. Miller 2018 
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